[go: up one dir, main page]

WO1997003066A1 - Substituted benzolactam compounds as substance p antagonists - Google Patents

Substituted benzolactam compounds as substance p antagonists Download PDF

Info

Publication number
WO1997003066A1
WO1997003066A1 PCT/IB1996/000434 IB9600434W WO9703066A1 WO 1997003066 A1 WO1997003066 A1 WO 1997003066A1 IB 9600434 W IB9600434 W IB 9600434W WO 9703066 A1 WO9703066 A1 WO 9703066A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
methyl
methoxy
oxo
salts
Prior art date
Application number
PCT/IB1996/000434
Other languages
French (fr)
Inventor
Hiroaki Wakabayashi
Masaya Ikunaka
Original Assignee
Pfizer Pharmaceuticals Inc.
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Pharmaceuticals Inc., Pfizer Inc. filed Critical Pfizer Pharmaceuticals Inc.
Priority to US08/983,004 priority Critical patent/US6180647B1/en
Priority to DK96911079T priority patent/DK0840732T3/en
Priority to DE69612003T priority patent/DE69612003T2/en
Priority to AT96911079T priority patent/ATE199552T1/en
Priority to JP9505628A priority patent/JP3042894B2/en
Priority to EP96911079A priority patent/EP0840732B1/en
Priority to CA002226292A priority patent/CA2226292C/en
Priority to MX9800187A priority patent/MX9800187A/en
Publication of WO1997003066A1 publication Critical patent/WO1997003066A1/en
Priority to US09/605,471 priority patent/US6288225B1/en
Priority to GR20010400624T priority patent/GR3035774T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Definitions

  • This invention relates to substituted benzolactam and cyclicthioamide compounds of interest to those in the field of medical chemistry and chemotherapy. More particularly, it is concerned with a series of substituted benzolactam and cyclicthioamide compounds, including their pharmaceutically acceptable salts, which are of special value in view of their ability to antagonize substance P. These compounds are of use in treating gastrointestinal disorders, central nervous system (CNS) disorders, inflammatory diseases, emesis, urinary incontinence, pain, migraine, angiogensis or the like, especially CNS disorders in a mammalian subject, especially humans.
  • CNS central nervous system
  • Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt stimulatory action on smooth muscle tissue. More specially, substance P is a pharmaceutically active neuropeptide that is produced in mammals (having originally been isolated from gut) and possesses a characteristic amino acid sequence that is illustrated by D. F. Veber et al. in US Pat. 4680283. The wide involvement of substance P and other tachykinins in the pathophysiology of numerous diseases has been amply demonstrated in the art.
  • substance P has recently been shown to be involved in the transmission of pain or migraine, as well as in central nervous system disorders such as anxiety and schizophrenia, in respiratory and inflammatory diseases such as asthma and rheumatoid arthritis, respectively, and in gastrointestinal disorders and diseases of GI tract, like ulcerative colitis and Crohn's diseases, etc. It is also reported that the tachykinin antagonists are useful for the treatment of allergic conditions, immunoregulation, vasodilation, bronchospasm, reflex or neuronal control of the viscera and senile dementia of the Alzheimer type, emesis, sunburn and Helicobacter pylori infection.
  • WO 94/13663 discloses a wide variety of azaheterocyclic compounds as tachykinin antagonists such as substance P antagonists. However, none of the compounds specifically disclosed in the references have good activity against CNS disorders with decreased adverse effects (e.g., Ca 2+ channel binding affinity).
  • the present invention provides substituted benzolactam and cyclicthioamide compounds of the following chemical formula (I):
  • W is methylene, ethylene, propylene, vinylene, -CH 2 -O-, -O-CH 2 -, -CH 2 -S- or - S-CH 2 -;
  • R 1 , R 2 and R 3 are independently hydrogen, C r C 3 alkyl, C,-C 3 alkoxy or halo Cj-C 3 alkyl, provided that when W is methylene, both R 2 and R 3 are not hydrogen;
  • X is halo, C r C 3 alkoxy, C,-C 3 alkyl, halo C r C 3 alkoxy or C,-C 3 alkenyl;
  • Y is imino or oxy
  • Q is oxygen or sulfur
  • T is (25,5-S)-2-diphenylmethylquinuclidin-3-yl, (2S,55)-2-phenylpiperidin-3-yl or (2S,55)-2-diphenylmethyl-l-azanorbornan-3-yl.
  • this invention includes an intermediate compound useful for preparation of the compounds of formula (I), which is (25',55)-3-amino-l-(tert-butoxycarbonyl)-2- phenylpiperidine .
  • the compounds of the present invention of formula (I) exhibit good antagonist activity toward Substance P, particularly good activity agaisnt CNS disorders with decreased side effects (e.g., Ca 2+ channel affinity), and are thus useful for treatment of a gastrointestinal disorder, a central nervous system disorder, an inflammatory disease, emesis, urinary incontinence, pain, migraine or angiogensis in a mammalian subject, especially human.
  • Substance P particularly good activity agaisnt CNS disorders with decreased side effects (e.g., Ca 2+ channel affinity)
  • side effects e.g., Ca 2+ channel affinity
  • the present invention provides a pharmaceutical composition for the treatment of a gastrointestinal disorder, a central nervous system disorder, an inflammatory disease, emesis, urinary incontinence, pain, migraine or angiogensis in a mammalian subject, which comprises a therapeutically effective amount of a compound of the formula (I) together with a pharmaceutically acceptable carrier.
  • halo C r C 3 alkyl is used herein to mean a C C 3 alkyl radical substituted with one or more halogens (e.g., Cl, F, I or Br) including, but not limited to, chloromethyl, trifluoromethyl, 2,2,2-trichloroethyl and the like; and the term “halo C r C 3 alkoxy” is used herein to mean a C,-C 3 alkoxy radical substituted with one or more halogens (e.g., Cl, F, I or Br) including, but not limited to, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy and the like.
  • halogens e.g., Cl, F, I or Br
  • a preferred group of compounds of this invention includes the compounds of formula (I) wherein R 1 , R 2 and R 3 are independently hydrogen, C,-C 3 alkyl, C r C 3 alkoxy or halo C r C 3 alkyl, provided that when W is methylene, both R 2 and R 3 are not hydrogen; X is C r C 3 alkoxy or halo C r C 3 alkoxy; Y is imino; and T is (2S,3S)-2- diphenylmethylquinuclidin-3-yl or (25,55)-2-phenylpiperidin-3-yl.
  • a particularly preferred group of compounds of the invention includes the compounds of formula (I), wherein R 1 is methyl, isopropyl, methoxy or 2,2,2- trifuluoroethyl; R 2 and R 3 are independently hydrogen, methyl or trifluoromethyl, provided that when W is methylene, both R 2 and R 3 are not hydrogen; and X is methoxy, isopropoxy, difluoromethoxy or trifuluoromethylmethoxy.
  • W is methylene
  • T-Y-CH 2 - and X are preferably at 5- or 6-position on the benzolactam ring.
  • T-Y-CH 2 - and X are preferably at 6- or 7- position on the benzolactam ring.
  • X and T-Y-CH 2 - are preferably at 6- or 7- position on the benzoxadine and benzothiadine ring.
  • W is propylene
  • X and T-Y-CH 2 - are preferably 7- or 8- position on the benzazepin ring, respectively.
  • Preferred individual compounds of this invention are the following: (2S,3S)-3-(6-methoxy- l ,3 ,3-trimethyloxindol-5-yl)methylamino-2- phenylpiperidine or its salts;
  • Particulaly preferred individual compounds of this invention are the following: (2S, 55')-2-diphenylmethyl-3-(6-methoxy- 1 ,3 , 3-trimethyloxindol-5- yl)methylamino-l-azabicyclo[2.2.2]octane or its salts;
  • the reduction can be carried out by catalytic hydrogenation, or with several hydride reagents in a reaction-inert solvent.
  • the catalytic hydrogenation may be carried out in the presence of a metal catalyst such as palladium or Raney nickel.
  • Suitalbe hydride reagents include borohydrides such as sodium borohydride (NaBH 4 ), sodium cyanoborohydride (NaBH 3 CN) and sodium triacetoxyborohydride (NaB(OAc) 3 H), boranes, aluminum-based reagents and trialkylsilanes.
  • Suitable solvents include polar solvents such as methanol, ethanol, methylene chloride, tetrahydrofuran (THF), dioxane and ethylacteate. This reaction is typically carried out at a temperature from -78 °C to reflux temperature of the solvent, preferably from 0 °C to 25 °C for 5 minutes to 48 hours, preferably from 0.5 to 12 hours.
  • the compounds of the formula (I) of this invention may be prepared by a reaction of a compound of the formula (III) with a compound of the formula: T-Y-H.
  • the compound (III) may be treated with T- NH 2 in the presence of a base (e.g., K 2 CO 3 or Na 2 CO 3 ) in a polar solvent (e.g. , methanol, ethanol, isopropylalcohol, THF, dioxane, dimethylformamide (DMF) or dimethylsulfoxide (DMSO)).
  • a base e.g., K 2 CO 3 or Na 2 CO 3
  • a polar solvent e.g. , methanol, ethanol, isopropylalcohol, THF, dioxane, dimethylformamide (DMF) or dimethylsulfoxide (DMSO)
  • the compound (III) may be treated with T-OH in the presence of a base (e.g., NaH or KH) in a polar solvent (e.g., THF, dioxane, DMF or DMSO). This reaction is typically carried out at a temperature from -78 °C to reflux temperature of the solvent, preferably from 0°C to 25 °C for 5 minutes to 48 hours, preferably from 0.5 to 12 hours.
  • the compounds (III) may be prepared by reduction of an aldehyde of the formula (II), followed by conversion of a hydroxy group of the resultant compound into a leaving group, Z.
  • Reduction of the aldehyde (II) may be accomplished using a variety of reducing agents in a reaction-inert solvent.
  • Suitable reducing agent/solvent systems include sodium tetrahydroborate (NaBH 4 ) in methanol or ethanol; lithium tetrahydroborate (LiBH 4 ) in THF or diethyl ether; lithium tetrahydroaluminium (IJA1H 4 ), lithium triethoxyhydroaluminium (LiAl(OEt) 3 H) lithium tert- buthoxyhydroaluminium (LiAl(OBut) 3 H) or aluminium trihydride (A1H 3 ) in THF or diethyl ether; and wo-buthyl aluminium hydride( -BuAlH 2 ) or diisopropyl aluminum hydride (DIBAL-H) in dichloromethane, THF or n-hexane.
  • NaBH 4 sodium
  • This reaction is generally carried out at a temperature from -20°C to 25°C for 5 minutes to 12 hours.
  • the hydroxy group of the resultant compound is converted to a leaving group, Z (e.g. , halo such as chloro, bromo, iodo or fluoro, or sulfonate including tosylate or mesylate).
  • Z e.g. , halo such as chloro, bromo, iodo or fluoro, or sulfonate including tosylate or mesylate.
  • Conversion of the hydroxy group into the leaving group, Z may be accomplished according to methods known to those skilled in the art. For example, when Z is sulfonate such as tosylate or mesylate, the hydroxy compound is reacted with sulfonate in the presence of pyridine or triethylamine in dichloromethane.
  • Z is halo such as chloro or bromo
  • the hydroxy compound may
  • the compounds of the formula (II) may be prepared by direct or indirect formylation of a compound of the formula (IV). Any formylation methods known to those skilled in the art may be used, to introduce a formyl group into a benzene ring. For example, direct formylation may be acomplished by contacting the compound (IV) with a suitable formylating agent in the presence of a suitable catalyst.
  • Suitable formylating agent/catalyst systems include dichloromethyl methyl ether / titanium (IV) chloride (Cl 2 CHOCH 3 /TiCl 4 ), trifluoroacetic acid (CF 3 CO 2 H) /hexamethylenetetramine (modified Duffs conditions) and phosphoryl trichloride (POCl 3 )/DMF (Vilsmeier's conditions).
  • Indirect formylation may be achieved by halogenating the compound (IV), displacing the halogen atom introduced with a cyano group, and then subjecting the resultant cyano-substituted compound to reduction.
  • the halogenation as used herein may be carried out according to the procedure reported in G. A.
  • the compound (II) wherein W is vinylene can be prepared by dehydrogenation of the formula (II) wherein W is ethylene in a suitable solvent such as dioxane.
  • the starting materials of the formula (IV) are known compounds which are commercially available, or can be prepared by known methods.
  • compounds of the formula (IV) wherein R 1 is alkyl can be prepared by N-alkylation of the corresponding compounds (IV) wherein R 1 is hydrogen, in the presence of a base (e.g., ⁇ aH or KH) in a suitalbe solvent (e.g., DMSO, DMF and THF).
  • a base e.g., ⁇ aH or KH
  • a suitalbe solvent e.g., DMSO, DMF and THF
  • Compoumds of the formula (IV) wherein R 2 or R 3 is not hydrogen can be also prepared from the corresponding compounds (IV) wherein R 2 or R 3 is hydrogen, using similar techniques as described above.
  • Compounds (IV) can be also prepared by other methods as described in European Patent No. 385662 and C.
  • Compound (IV) wherein Q is S can be prepared by thionation of the corresponding compound (IV) wherein Q is O. Suitable thionation agents are Lawesson reagent (Tetrahedron. 41. 5061 (1985)) and P 4 S 10 (Chem. Pharm. Bull.. 10. 647 (1962)).
  • N-protection of a compound of the formula (V) may be carried out by treatment with (t-BuOCO) 2 O (Boc 2 O) in the presence of a base such as sodium bicarbonate (NaHCO 3 ) or triethylamine (Et 3 N) to obtain a compound of the formula (VI).
  • a base such as sodium bicarbonate (NaHCO 3 ) or triethylamine (Et 3 N)
  • Compound (VI) is subjeted to hydrogenolysis to obtain a compound of the formula (VII) (wherein R 5 is phenyl; and R 6 is t-butoxycarbonyl.
  • An alternative route for N-protection of a compound of the formula (V) may be carried out by treatment with carbobenzoxy chloride (Cbz-Cl) in the presence of a base such as sodium bicarbonate (NaHCO 3 ) or triethylamine (Et 3 N), wherein R 5 is phenyl; and R 6 is benzyloxycarbonyl.
  • the hydrogenolysis may be carried out by treatment with H 2 or ammonium formate (HCO 2 NH 4 ) in the presence of a metal catalyst such as a palladium on charcoal (e.g. 20% palladium on charcole) in a suitable solvent.
  • a metal catalyst such as a palladium on charcoal (e.g. 20% palladium on charcole) in a suitable solvent.
  • the compound (VIII) may be converted into a compound of the formula (Ia) by treatment with acid catalyst such as hydrochloride (HCl) in methanol, cone. HCl in ethylacetate or CF 3 CO 2 H in dichloroethane.
  • acid catalyst such as hydrochloride (HCl) in methanol, cone. HCl in ethylacetate or CF 3 CO 2 H in dichloroethane.
  • the compounds of formula (I) of this invention possess at least two asymmetric centers, they are capable of occurring in various stereoisomeric forms or configurations. Hence, the compounds can exist in separated (+)- and (-)-optically active forms, as well as mixtures thereof.
  • the present invention includes all such forms within its scope. Individual isomers can be obtained by known methods, such as optical resolution, optically selective reaction, or chromatographic separation in the preparation of the final product or its intermediate.
  • the compounds of formula (I) of this invention are basic compounds, they are all capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the base compound from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert to the free base compound by treatment with an alkaline reagent and thereafter convert the free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.
  • the acid which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bi-tartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, ptoluenesulfonate and pamoate (i.e. , 1 J '-methylene-bis-(2-hydroxy- 3-naphthoate))salts.
  • non-toxic acid addition salts i.e., salts containing pharmaceutically acceptable anions, such as the hydroch
  • the compounds of the invention which have also acidic groups are capable of forming base salts with various pharmaceutically acceptable cations.
  • such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques.
  • the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic derivatives. These particular non-toxic base salts include those derived form such pharmaceutically acceptable cations as sodium, potassium, calcium and magnesium, etc.
  • salts can easily be prepared by treating the aforementioned acidic compounds with an aqueous solution containing the desired pharmaceutically acceptable cation, and then evaporating the resulting solution to dryness, preferably under reduced pressure.
  • they may also be prepared by mixing lower alkanoic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before.
  • stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum production of yields of the desired final product.
  • the active compounds of the present invention exhibit significant substance P receptor-binding activity and therefore, are of value in the treatment of a wide variety of clinical conditions which are characterized by the presence of an excess of said substance P activity.
  • Such conditions include gastrointestinal disorders, central nervous system disorders, inflammatory diseases, emesis, urinary incontinence, pain, migraine or angiogensis in a mammalian subject, especially humans.
  • the active compounds of the formula (I) of this invention can be administered via either the oral, parenteral or topical routes to mammals.
  • these compounds are most desirably administered to humans in doses ranging from about 0.3 mg up to 750 mg per day, although variations will necessarily occur depending upon the weight and condition of the subject being treated and the particular route of administration chosen.
  • a dosage level that is in the range of from about 0.06 mg to about 2 mg per kg of body weight per day is most desirably employed. Nevertheless, variations may still occur depending upon the species of animal being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out.
  • dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effects provided that such higher dose levels are first divided into several small doses for administration throughout the day.
  • the compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by either of the above routes previously indicated, and such administration can be carried out in single or multiple doses. More particularly, the novel therapeutic agents of the invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like.
  • Such carriers include solid diluents or fillers, sterile aqueous media and various nontoxic organic solvents, etc.
  • oralpharmaceutical compositions can be suitably sweetened and/or flavored.
  • the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging about 5.0% to about 70% by weight.
  • tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch and preferably corn, potato or tapioca starch, alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • disintegrants such as starch and preferably corn, potato or tapioca starch, alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes.
  • compositions of a similar type may also be employed as fillers in gelatine capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene grycols.
  • the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • solutions of a compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed.
  • the aqueous solutions should be suitably buffered (preferably pH > 8) if necessary and the liquid diluent first rendered isotonic.
  • These aqueous solutions are suitable for intravenous injection purposes.
  • the oily solutions are suitable for intra-articular, intra ⁇ muscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.
  • the activity of the compounds of the present invention is determined by their ability to inhibit the binding of substance P at its receptor sites in CHO-cells which reveal NKI receptor or IM-9 cells employing radioactive ligands.
  • the substance P antagonist activity of the herein described compounds is evaluated by using the standard assay procedure described by D. G. Payan et al., as reported in the The Journal of Immunology . 133. 3260 (1984). This method essentially involves determining the concentration of the individual compound required to reduce by 50% the amount of radiolabelled substance P ligands at their receptor sites in said isolated cow tissues or IM-9 cells, thereby affording characteristic IC 50 values for each compound tested.
  • inhibition of [ 3 H]SP binding to human IM-9 cells by compounds are determined in assay buffer (50 mM Tris-HCl (pH 7.4), 1 mM MnCl 2 , 0.02 % bovine serum albumin, bacitracin (40 ⁇ g/ml), leupeptin (4 ⁇ g/ml), chymostatin (2 ⁇ g/ml) and phosphoramidon (30 ⁇ g/ml)).
  • assay buffer 50 mM Tris-HCl (pH 7.4), 1 mM MnCl 2 , 0.02 % bovine serum albumin, bacitracin (40 ⁇ g/ml), leupeptin (4 ⁇ g/ml), chymostatin (2 ⁇ g/ml) and phosphoramidon (30 ⁇ g/ml).
  • assay buffer 50 mM Tris-HCl (pH 7.4), 1 mM MnCl 2 , 0.02 % bovine serum albumin, bacitracin
  • Incubation is terminated by filtration onto GF/B filters (presoaked in 0.1 % polyethylenimine for 2 hours).
  • Nonspecific binding is defined as the radioactivity remaining in the presence of 1 ⁇ M SP.
  • the filters are placed into tubes and counted using liquid scintillation counter.
  • the adverse effect on Ca 2+ channel binding affinity is determined by verapamil binding study in rat heart membrane preparation. More specifically, verapamil binding study is performed as previously described by Reynolds et al. , (J. Pharmacol. Exp. Ther. 237, 731, 1986). Briefly, incubations are initiated by the addition of tissue to tubes containing 0.25 nM [ 3 H]desmethoxyverapamil and various concentrations of compounds (total volume; 1 ml). Nonspecific binding is defined as radioligand binding remaining in the presence of 3-10 ⁇ M methoxyverapamil.
  • the activity of the compounds of this invention against CNS disorder is determined by [Sar 9 , Met(O 2 ) ⁇ ]substance P-induced tapping test in gerbils. More specifically, gerbils are lightly anesthetized with ether and the skull surface is exposed. [Sar 9 , Met(O 2 ) n ]substance P or vehicle (5 ⁇ l) are administered directly into the lateral ventricles via a 25 gauge needle inserted 3.5 mm below lambda. Following injection, gerbils are placed in 2 1 beaker individually and monitored for repetitive hind paw tapping. Some compounds prepared in the following Examples were tested in accordance with these testing methods. As a result, it was found that the compounds of the present inventions have good agonist activity toward Substance P, particularly good activity agaisnt CNS disorders with decreased side effects.
  • the title compound 3 was prepared from compound 2 by applying the method reported by Rieche, A. , Gross, H., and Hoft, E. (Org. Svnth. Coll. Vol., V, 49).
  • Reductive alkylation of compound 4 with compound 3 was carried out according to the procedures reported by Abdel-Magid, A.F., Maryanoff, C.A., and Carson, K.G. (Tetrahedron Lett.. 31, 5595 (1990)).
  • This compound was prepared according to the procedures disclosed in WO-93- 01170.
  • Reductive alkylation of compound 9 with compound 3 was carried out according to the procedures reported by Abdel-Magid, A.F., Maryanoff, C.A., and Carson, K.G. (Tetrahedron Lett.. 31, 5595 (1990)).
  • the compound obtained was subjected to the IM-9 binding assay, the [Sar 9 , Met(O 2 )"]substance P-induced tapping test and the verapamil binding study as described before, with the results of less than OJnM, 52% (% inhibition at 0.3mg/kg scoring) and more than 3000nM, respectively.
  • This compound was prepared from compound 32 in the same manner of compound 12. mp 257 - 260 °C. IR v w (KBr) 3440, 2960, 2925, 1665, 1554, 1506, 1464, 1455, 1435, 1412, 1372, 1355, 1326, 1316, 1234, 1196, 1141, 1033 cm"'.
  • This compound was prepared from compound 16 in the same manner of compound 22.
  • This compound was prepared from compound 36 in the same manner of compound 12. mp 238 - 240 °C. IR ⁇ (KBr) 3440, 2930, 2763, 2475, 1681, 1521 , 1431 , 1116, 1044 cm '.
  • This compound was prepared from compound 29 and CH 3 SO 3 CH 2 CF 3 in the same manner of compound 30.
  • This compound was prepared from compound 21 and CH 3 SO 3 CH 2 CF 3 in the same manner of compound 23.
  • This compound was prepared from compound 50 in the same manner of compound 3.
  • This compound was prepared from compound 51 in the same manner of compound 30.
  • This compound was prepared from compound 63 and compound 9 in the same manner of compound 11.
  • This compound was prepared from compound 68 and compound 9 in the same manner of compound 11.
  • This compound was prepared from compound 71 in the same manner of compound 30.
  • This compound was prepared from compound 73 and compound 9 in the same manner of compound 11.
  • This compound was prepared from compound 74 in the same manner of compound 12. mp 252 - 254 °C. IR ⁇ max (KBr) 3450, 2935, 2655, 1647, 1562, 1514, 1470, 1450, 1434, 1416, 1269, 1166, 1038 cm '.
  • This compound was prepared from compound 76 in the same manner of compound 3.
  • This compound was prepared according to the procedure (US 4552956).
  • This compound was prepared from compound 81 and compound 9 in the same manner of compound 11.
  • This compound was prepared from compound 84 in the same manner of compound 3.
  • This compound was prepared from compound 86 in the same manner of compound 12. mp 234 - 236 °C. IR v w (KBr) 3435, 2970, 2934, 2685, 1627, 1559, 1447, 1430, 1370, 1278, 1056 cm '.
  • This compound was prepared from compound 55 in the same manner of compound 46.
  • This compound was prepared from compound 88 in the same manner of compound 3.
  • This compound was prepared from compound 92 in the same manner of compound 3.
  • This compound was prepared from compound 93 and compound 9 in the same manner of compound 11. This was employed in the next step without further purification.
  • This compound was prepared from compound 96 and CF 2 HC1 in the same manner of compound 30.
  • This compound was prepared from compound 97 and compound 9 in the same manner of compound 11.
  • This compound was prepared from compound 98 in the same manner of compound 12.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention provides a compound of general formula (I) and its pharmaceutically acceptable salts, wherein: W is methylene, ethylene, propylene, vinylene, -CH2-O-, -O-CH2-, -CH2-S- or -S-CH2-; R?1, R2 and R3¿ are independently hydrogen, C¿1?-C3 alkyl, C1-C3 alkoxy or halo C1-C3 alkyl, provided that when W is methylene, both R?2 and R3¿ are not hydrogen; X is halo, C¿1?-C3 alkoxy, C1-C3 alkyl, halo C1-C3 alkoxy or C1-C3 alkenyl; Y is imino or oxy; Q is oxygen or sulfur; and T is (2S,3S)-2-diphenylmethylquinuclidin-3-yl, (2S,3S)-2-phenylpiperidin-3-yl or (2S,3S)-2-diphenylmethyl-1-azanorbornan-3-yl. These compounds are useful in the treatment of treating gastrointestinal disorders, central nervous system disorders, inflammatory diseases, emesis, urinary incontinence, pain, migraine, angiogensis or the like in a mammaliam subject, especially humans. Also, intermediates of the above compounds are disclosed.

Description

SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS
Technical Held
This invention relates to substituted benzolactam and cyclicthioamide compounds of interest to those in the field of medical chemistry and chemotherapy. More particularly, it is concerned with a series of substituted benzolactam and cyclicthioamide compounds, including their pharmaceutically acceptable salts, which are of special value in view of their ability to antagonize substance P. These compounds are of use in treating gastrointestinal disorders, central nervous system (CNS) disorders, inflammatory diseases, emesis, urinary incontinence, pain, migraine, angiogensis or the like, especially CNS disorders in a mammalian subject, especially humans.
Background Art Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt stimulatory action on smooth muscle tissue. More specially, substance P is a pharmaceutically active neuropeptide that is produced in mammals (having originally been isolated from gut) and possesses a characteristic amino acid sequence that is illustrated by D. F. Veber et al. in US Pat. 4680283. The wide involvement of substance P and other tachykinins in the pathophysiology of numerous diseases has been amply demonstrated in the art. For instance, substance P has recently been shown to be involved in the transmission of pain or migraine, as well as in central nervous system disorders such as anxiety and schizophrenia, in respiratory and inflammatory diseases such as asthma and rheumatoid arthritis, respectively, and in gastrointestinal disorders and diseases of GI tract, like ulcerative colitis and Crohn's diseases, etc. It is also reported that the tachykinin antagonists are useful for the treatment of allergic conditions, immunoregulation, vasodilation, bronchospasm, reflex or neuronal control of the viscera and senile dementia of the Alzheimer type, emesis, sunburn and Helicobacter pylori infection.
International Publication No. WO 94/13663 discloses a wide variety of azaheterocyclic compounds as tachykinin antagonists such as substance P antagonists. However, none of the compounds specifically disclosed in the references have good activity against CNS disorders with decreased adverse effects (e.g., Ca2+ channel binding affinity).
Brief Description of the Invention
The present invention provides substituted benzolactam and cyclicthioamide compounds of the following chemical formula (I):
Figure imgf000004_0001
and its pharmaceutically acceptable salts, wherein
W is methylene, ethylene, propylene, vinylene, -CH2-O-, -O-CH2-, -CH2-S- or - S-CH2-;
R1, R2 and R3 are independently hydrogen, CrC3 alkyl, C,-C3 alkoxy or halo Cj-C3 alkyl, provided that when W is methylene, both R2 and R3 are not hydrogen;
X is halo, CrC3 alkoxy, C,-C3 alkyl, halo CrC3 alkoxy or C,-C3 alkenyl;
Y is imino or oxy;
Q is oxygen or sulfur; and
T is (25,5-S)-2-diphenylmethylquinuclidin-3-yl, (2S,55)-2-phenylpiperidin-3-yl or (2S,55)-2-diphenylmethyl-l-azanorbornan-3-yl.
Also, this invention includes an intermediate compound useful for preparation of the compounds of formula (I), which is (25',55)-3-amino-l-(tert-butoxycarbonyl)-2- phenylpiperidine .
The compounds of the present invention of formula (I) exhibit good antagonist activity toward Substance P, particularly good activity agaisnt CNS disorders with decreased side effects (e.g., Ca2+ channel affinity), and are thus useful for treatment of a gastrointestinal disorder, a central nervous system disorder, an inflammatory disease, emesis, urinary incontinence, pain, migraine or angiogensis in a mammalian subject, especially human. Accordingly, the present invention provides a pharmaceutical composition for the treatment of a gastrointestinal disorder, a central nervous system disorder, an inflammatory disease, emesis, urinary incontinence, pain, migraine or angiogensis in a mammalian subject, which comprises a therapeutically effective amount of a compound of the formula (I) together with a pharmaceutically acceptable carrier.
Detailed Description of the Invention In this specification, the term "halo CrC3 alkyl" is used herein to mean a C C3 alkyl radical substituted with one or more halogens (e.g., Cl, F, I or Br) including, but not limited to, chloromethyl, trifluoromethyl, 2,2,2-trichloroethyl and the like; and the term "halo CrC3 alkoxy" is used herein to mean a C,-C3 alkoxy radical substituted with one or more halogens (e.g., Cl, F, I or Br) including, but not limited to, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy and the like.
A preferred group of compounds of this invention includes the compounds of formula (I) wherein R1, R2 and R3 are independently hydrogen, C,-C3 alkyl, CrC3 alkoxy or halo CrC3 alkyl, provided that when W is methylene, both R2 and R3 are not hydrogen; X is CrC3 alkoxy or halo CrC3 alkoxy; Y is imino; and T is (2S,3S)-2- diphenylmethylquinuclidin-3-yl or (25,55)-2-phenylpiperidin-3-yl.
A particularly preferred group of compounds of the invention includes the compounds of formula (I), wherein R1 is methyl, isopropyl, methoxy or 2,2,2- trifuluoroethyl; R2 and R3 are independently hydrogen, methyl or trifluoromethyl, provided that when W is methylene, both R2 and R3 are not hydrogen; and X is methoxy, isopropoxy, difluoromethoxy or trifuluoromethylmethoxy. When W is methylene, T-Y-CH2- and X are preferably at 5- or 6-position on the benzolactam ring. When W is ethylene or vinylene, T-Y-CH2- and X are preferably at 6- or 7- position on the benzolactam ring. When W is -CH2-O-, -O-CH2-, -CH2-S- or -S-CH2-, X and T-Y-CH2- are preferably at 6- or 7- position on the benzoxadine and benzothiadine ring. When W is propylene, X and T-Y-CH2- are preferably 7- or 8- position on the benzazepin ring, respectively.
Preferred individual compounds of this invention are the following: (2S,3S)-3-(6-methoxy- l ,3 ,3-trimethyloxindol-5-yl)methylamino-2- phenylpiperidine or its salts;
(25,55)-3-(6-methoxy-l-methyl-2-oxo-l ,2,3 ,4-tetrahydroquinolin-7- yl)methylamino-2-phenylpiperidine or its salts; (2S,5S)-3-(6-isopropoxy- l-methyl-2-oxo-l ,2,3,4-tetrahydroquinolin-7- yι)methylamino-2-phenylpiperidine or its salts;
(2S,3S)-3-(l-isopropyl-6-methoxy-2-oxo-l ,2,3,4-tetrahydroquinolin-7- yl)methylamino-2-phenylpiperidine or its salts; 25',55'J-3-[(6-methoxy-l-methyl-2-thioxo-l ,2,3,4-tetrahydroquinolin-7- yl)methyl]amino-2-phenylpiperidine dihydrochloride or its salts;
(2S,55 3-[(7-methoxy-l-methyl-2-oxo- 1 ,2,3, 4-tetrahydroquinolin-6- yl)methyl]amino-2-phenylpiperidine dihydrochloride or its salts; and
(25,55j-3-[(6-methoxy-l-methyl-2-oxo-4H-3, l-benzothiazin-7-yl)methyl]amino- 2-phenylpiperidine dihydrochloride or its salts.
Particulaly preferred individual compounds of this invention are the following: (2S, 55')-2-diphenylmethyl-3-(6-methoxy- 1 ,3 , 3-trimethyloxindol-5- yl)methylamino-l-azabicyclo[2.2.2]octane or its salts;
(25, 5)-2-diphenylmethyl-3-(6-methoxy- l -methyl-2-oxo- l ,2 , 3 ,4- tetrahydroquinolin-7-yl)methylamino-l-azabicyclo[2.2.2]octane or its salts;
(2S,55)-2-diphenylmethyl-3-(6-methoxy-l-methyl-2-oxo-l,2-dihydroquinolin-7- yl)methylamino-l-azabicyclo[2.2.2]octane or its salts;
(2S, 55'J-3-[(6-methoxy- 1 -methyl-2-thioxo- 1 ,2 , 3 ,4-tetrahydroquinolin-7- yl)methyl]amino-2-phenylpiperidine dihydrochloride or its salts; and (2S,5S 3-[(6-methoxy-l-rnethyl-2-oxo-4H-3 , 1 -benzothiazin-7-yl)methyl]arnino-
2-phenylpiperidine dihydrochloride or its salts.
General Synthesis The compounds of the formula (I) of this invention may be prepared as described in the following reaction schemes. Unless otherwise indicated, in the reaction schemes that follow, R1, R2, R3, X,
Y, Z, W, Q and T are defined as above. Scheme A-I
Figure imgf000007_0001
Scheme A-I illustrates a method for preparing compounds of the formula (I) by reductive amination of a compound of the formula (II) with a compound of the formula: T-NH2 (Y=NH). The reduction can be carried out by catalytic hydrogenation, or with several hydride reagents in a reaction-inert solvent. The catalytic hydrogenation may be carried out in the presence of a metal catalyst such as palladium or Raney nickel. Suitalbe hydride reagents include borohydrides such as sodium borohydride (NaBH4), sodium cyanoborohydride (NaBH3CN) and sodium triacetoxyborohydride (NaB(OAc)3H), boranes, aluminum-based reagents and trialkylsilanes. Suitable solvents include polar solvents such as methanol, ethanol, methylene chloride, tetrahydrofuran (THF), dioxane and ethylacteate. This reaction is typically carried out at a temperature from -78 °C to reflux temperature of the solvent, preferably from 0 °C to 25 °C for 5 minutes to 48 hours, preferably from 0.5 to 12 hours.
Alternatively, the compounds of the formula (I) of this invention may be prepared as shown in the following scheme A-II. Scheme A-II
Figure imgf000007_0002
(wherein Z s a eav ng group such as a o or su onate nc ud ng tosylate or mesylate)
Referring to Scheme A-II, the compounds of the formula (I) of this invention may be prepared by a reaction of a compound of the formula (III) with a compound of the formula: T-Y-H. When Y is NH, the compound (III) may be treated with T- NH2 in the presence of a base (e.g., K2CO3 or Na2CO3) in a polar solvent (e.g. , methanol, ethanol, isopropylalcohol, THF, dioxane, dimethylformamide (DMF) or dimethylsulfoxide (DMSO)). When Y is O, the compound (III) may be treated with T-OH in the presence of a base (e.g., NaH or KH) in a polar solvent (e.g., THF, dioxane, DMF or DMSO). This reaction is typically carried out at a temperature from -78 °C to reflux temperature of the solvent, preferably from 0°C to 25 °C for 5 minutes to 48 hours, preferably from 0.5 to 12 hours. The compounds (III) may be prepared by reduction of an aldehyde of the formula (II), followed by conversion of a hydroxy group of the resultant compound into a leaving group, Z. Reduction of the aldehyde (II) may be accomplished using a variety of reducing agents in a reaction-inert solvent. Suitable reducing agent/solvent systems include sodium tetrahydroborate (NaBH4) in methanol or ethanol; lithium tetrahydroborate (LiBH4) in THF or diethyl ether; lithium tetrahydroaluminium (IJA1H4), lithium triethoxyhydroaluminium (LiAl(OEt)3H) lithium tert- buthoxyhydroaluminium (LiAl(OBut)3H) or aluminium trihydride (A1H3) in THF or diethyl ether; and wo-buthyl aluminium hydride( -BuAlH2) or diisopropyl aluminum hydride (DIBAL-H) in dichloromethane, THF or n-hexane. This reaction is generally carried out at a temperature from -20°C to 25°C for 5 minutes to 12 hours. Then, the hydroxy group of the resultant compound is converted to a leaving group, Z (e.g. , halo such as chloro, bromo, iodo or fluoro, or sulfonate including tosylate or mesylate). Conversion of the hydroxy group into the leaving group, Z may be accomplished according to methods known to those skilled in the art. For example, when Z is sulfonate such as tosylate or mesylate, the hydroxy compound is reacted with sulfonate in the presence of pyridine or triethylamine in dichloromethane. When Z is halo such as chloro or bromo, the hydroxy compound may be treated with SOX2 (X is Cl or Br) in the presence of pyridine.
The compounds of the formula (II) can be prepared as illustrated in the following scheme B. Scheme B
Figure imgf000009_0001
The compounds of the formula (II) may be prepared by direct or indirect formylation of a compound of the formula (IV). Any formylation methods known to those skilled in the art may be used, to introduce a formyl group into a benzene ring. For example, direct formylation may be acomplished by contacting the compound (IV) with a suitable formylating agent in the presence of a suitable catalyst. Suitable formylating agent/catalyst systems include dichloromethyl methyl ether / titanium (IV) chloride (Cl2CHOCH3/TiCl4 ), trifluoroacetic acid (CF3CO2H) /hexamethylenetetramine (modified Duffs conditions) and phosphoryl trichloride (POCl3)/DMF (Vilsmeier's conditions). Indirect formylation may be achieved by halogenating the compound (IV), displacing the halogen atom introduced with a cyano group, and then subjecting the resultant cyano-substituted compound to reduction. The halogenation as used herein may be carried out according to the procedure reported in G. A. Olah et., al. J. Org Chem. 58, 3194 (1993). The displacement of the halogen atom with a cyano group may be perfomred according to the methods reported in D. M. Tschaem et. al. , Synth Commun. 24, 887 (1994), K. Takagi et. al., 64 Bull Chem. Soc. Jpn. 64, 1118 (1991). The reduction as used herein may be performed in the presence of diisopropyl aluminiumhydride (DIBAL-H) in dichloromethane or Raney nickel in formic acid.
In addition, the compound (II) wherein W is vinylene can be prepared by dehydrogenation of the formula (II) wherein W is ethylene in a suitable solvent such as dioxane.
The starting materials of the formula (IV) are known compounds which are commercially available, or can be prepared by known methods. For example, compounds of the formula (IV) wherein R1 is alkyl can be prepared by N-alkylation of the corresponding compounds (IV) wherein R1 is hydrogen, in the presence of a base (e.g., ΝaH or KH) in a suitalbe solvent (e.g., DMSO, DMF and THF). Compoumds of the formula (IV) wherein R2 or R3 is not hydrogen, can be also prepared from the corresponding compounds (IV) wherein R2 or R3 is hydrogen, using similar techniques as described above. Compounds (IV) can be also prepared by other methods as described in European Patent No. 385662 and C. Crestini. et. al. , Synth. Commun. 24 2853 (1994) or G. W. Rewcastle et. al. , J. Med Chem. 37, 2033 (1994). Compound (IV) wherein Q is S, can be prepared by thionation of the corresponding compound (IV) wherein Q is O. Suitable thionation agents are Lawesson reagent (Tetrahedron. 41. 5061 (1985)) and P4S10 (Chem. Pharm. Bull.. 10. 647 (1962)).
Alternatively, compounds of the formula (I) wherein T is 2-phenylpireridinyl and Y is NH, may be preapred as shown in the following Scheme A-III. Scheme A-III
Figure imgf000010_0001
Deprotection
Figure imgf000010_0002
1 da)
H Scheme A-III illustrates the preparation of compoumds of the formula (Ia) (corresponding to Compound (I) wherein T is 2-phenylpiperidinyl and Y is NH).
Referring to Scheme A-III, N-protection of a compound of the formula (V) (R4 is phenyl or the like) may be carried out by treatment with (t-BuOCO)2O (Boc2O) in the presence of a base such as sodium bicarbonate (NaHCO3) or triethylamine (Et3N) to obtain a compound of the formula (VI). Compound (VI) is subjeted to hydrogenolysis to obtain a compound of the formula (VII) (wherein R5 is phenyl; and R6 is t-butoxycarbonyl. An alternative route for N-protection of a compound of the formula (V) may be carried out by treatment with carbobenzoxy chloride (Cbz-Cl) in the presence of a base such as sodium bicarbonate (NaHCO3) or triethylamine (Et3N), wherein R5 is phenyl; and R6 is benzyloxycarbonyl. The hydrogenolysis may be carried out by treatment with H2 or ammonium formate (HCO2NH4) in the presence of a metal catalyst such as a palladium on charcoal (e.g. 20% palladium on charcole) in a suitable solvent. Then, the compound (VII) is subjected to the reductive amination as described in Scheme A-I. The compound (VIII) may be converted into a compound of the formula (Ia) by treatment with acid catalyst such as hydrochloride (HCl) in methanol, cone. HCl in ethylacetate or CF3CO2H in dichloroethane.
The compounds of formula (I), and the intermediates shown in the above reaction schemes can be isolated and purified by conventional procedures, such as recrystallization or chromatographic separation.
As the compounds of formula (I) of this invention possess at least two asymmetric centers, they are capable of occurring in various stereoisomeric forms or configurations. Hence, the compounds can exist in separated (+)- and (-)-optically active forms, as well as mixtures thereof. The present invention includes all such forms within its scope. Individual isomers can be obtained by known methods, such as optical resolution, optically selective reaction, or chromatographic separation in the preparation of the final product or its intermediate.
In so far as the compounds of formula (I) of this invention are basic compounds, they are all capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the base compound from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert to the free base compound by treatment with an alkaline reagent and thereafter convert the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The acid which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bi-tartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, ptoluenesulfonate and pamoate (i.e. , 1 J '-methylene-bis-(2-hydroxy- 3-naphthoate))salts.
The compounds of the invention which have also acidic groups are capable of forming base salts with various pharmaceutically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic derivatives. These particular non-toxic base salts include those derived form such pharmaceutically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can easily be prepared by treating the aforementioned acidic compounds with an aqueous solution containing the desired pharmaceutically acceptable cation, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanoic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum production of yields of the desired final product. The active compounds of the present invention exhibit significant substance P receptor-binding activity and therefore, are of value in the treatment of a wide variety of clinical conditions which are characterized by the presence of an excess of said substance P activity. Such conditions include gastrointestinal disorders, central nervous system disorders, inflammatory diseases, emesis, urinary incontinence, pain, migraine or angiogensis in a mammalian subject, especially humans.
The active compounds of the formula (I) of this invention can be administered via either the oral, parenteral or topical routes to mammals. In general, these compounds are most desirably administered to humans in doses ranging from about 0.3 mg up to 750 mg per day, although variations will necessarily occur depending upon the weight and condition of the subject being treated and the particular route of administration chosen. However, a dosage level that is in the range of from about 0.06 mg to about 2 mg per kg of body weight per day is most desirably employed. Nevertheless, variations may still occur depending upon the species of animal being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effects provided that such higher dose levels are first divided into several small doses for administration throughout the day.
The compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by either of the above routes previously indicated, and such administration can be carried out in single or multiple doses. More particularly, the novel therapeutic agents of the invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various nontoxic organic solvents, etc. Moreover, oralpharmaceutical compositions can be suitably sweetened and/or flavored. In general, the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging about 5.0% to about 70% by weight.
For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch and preferably corn, potato or tapioca starch, alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatine capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene grycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
For parenteral administration, solutions of a compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH > 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intra-articular, intra¬ muscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art. Additionally, it is also possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin and this may preferably be done by way of creams, jellies, gels, pastes, ointments and the like, in accordance with standard pharmaceutical practice.
The activity of the compounds of the present invention, as substance P antagonists, is determined by their ability to inhibit the binding of substance P at its receptor sites in CHO-cells which reveal NKI receptor or IM-9 cells employing radioactive ligands. The substance P antagonist activity of the herein described compounds is evaluated by using the standard assay procedure described by D. G. Payan et al., as reported in the The Journal of Immunology . 133. 3260 (1984). This method essentially involves determining the concentration of the individual compound required to reduce by 50% the amount of radiolabelled substance P ligands at their receptor sites in said isolated cow tissues or IM-9 cells, thereby affording characteristic IC50 values for each compound tested. More specifically, inhibition of [3H]SP binding to human IM-9 cells by compounds are determined in assay buffer (50 mM Tris-HCl (pH 7.4), 1 mM MnCl2, 0.02 % bovine serum albumin, bacitracin (40 μg/ml), leupeptin (4 μg/ml), chymostatin (2 μg/ml) and phosphoramidon (30 μg/ml)). The reaction is initiated by the addition of cells to assay buffer containing 0.56 nM [3H]SP and various concentrations of compounds (total volume; 0.5 ml) and allowed to incubate for 120 min at 4 °C. Incubation is terminated by filtration onto GF/B filters (presoaked in 0.1 % polyethylenimine for 2 hours). Nonspecific binding is defined as the radioactivity remaining in the presence of 1 μM SP. The filters are placed into tubes and counted using liquid scintillation counter. The adverse effect on Ca2+ channel binding affinity is determined by verapamil binding study in rat heart membrane preparation. More specifically, verapamil binding study is performed as previously described by Reynolds et al. , (J. Pharmacol. Exp. Ther. 237, 731, 1986). Briefly, incubations are initiated by the addition of tissue to tubes containing 0.25 nM [3H]desmethoxyverapamil and various concentrations of compounds (total volume; 1 ml). Nonspecific binding is defined as radioligand binding remaining in the presence of 3-10 μM methoxyverapamil.
The activity of the compounds of this invention against CNS disorder is determined by [Sar9, Met(O2)π]substance P-induced tapping test in gerbils. More specifically, gerbils are lightly anesthetized with ether and the skull surface is exposed. [Sar9, Met(O2)n]substance P or vehicle (5 μl) are administered directly into the lateral ventricles via a 25 gauge needle inserted 3.5 mm below lambda. Following injection, gerbils are placed in 2 1 beaker individually and monitored for repetitive hind paw tapping. Some compounds prepared in the following Examples were tested in accordance with these testing methods. As a result, it was found that the compounds of the present inventions have good agonist activity toward Substance P, particularly good activity agaisnt CNS disorders with decreased side effects.
EXAMPLES The present invention is illustrated by the following examples. However, it should be understood that the invention is not limited to the specific details of these examples. Melting points were taken with a Buchi micro melting point apparatus and uncorrected. Infrared Ray absorption spectra (IR) were measured by a Shimazu infrared spectrometer (IR-470). 'H and 13C nuclear magnetic resonance spectra (NMR) were measured in CDC13 by a JEOL NMR spectrometer (JNM-GX270, 270MHz for *H, 67.5MHz for 13C) unless otherwise indicated and peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane. The peak shapes are denoted as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad. Example 1
Preparation of (2S ,SV2-Diphenylmethyl-3-(6-methoxy-l .3.3-trimethyloxindol-5- yl')methylamino-l-azabicyclor2.2.21octane monobesylate (Compound 6) (0 6-Methoxyoxindole (Compound 1)
This compound was prepared according to Quallich and Morrissey's procedures (Synthesis 51(1993)).
(ii) 6-Methoxy-1.3.3-trimethyloxindole (Compound 2)
To a stirred and ice-cooled suspension of NaH [60% in oil, 3.93g, 98. Immol; washed with n-pentane (15.0ml) three times prior to use] in dry DMF (50.0ml) was added compound 1 (4.00g, 24.5mmol) portionwise. To this grey suspension was added neat Mel (6.11ml, d2.2S0, 98.1 mmol) dropwise with ice-cooling. The mixture was stirred at room temperature for 45 minutes. After the mixture was ice-cooled, H2O (90.0ml) was added. The mixture was extracted with ethyl acetate/toluene (AcOEt/PhMe) (2: 1; 70.0ml x3). The combined AcOEt/PhMe (2: 1) extracts were washed with Na2S2O3 aq. (xl), H2O (xl), and sat. NaCl aq. (xl), dried (MgSO4), treated with activated charcoal, and concentrated in vacuo to give a red syrup (5J8g). This was purified by medium pressure silica gel chromatography [Merck Kieselgel 60, lOOg; n-hexane-AcOEt (20: 1-15: 1-10: 1)] to give compound 2 (4.74g, 94.2%) as white crystals.
Η-NMR (270MHz) δ (CDC13) 7.09 (d, J = 8JHz, IH), 6.56 (dd, J = 8.1, 2.2Hz, IH), 6.44 (d, J = 2.2Hz,. IH), 3.83 (s, 3H), 3J9 (s, 3H), 1.34 (s, 6H) ppm. (111) 5-Formyl-6-methoxy-1.3.3-trimethyloxindole (Compound 31
The title compound 3 was prepared from compound 2 by applying the method reported by Rieche, A. , Gross, H., and Hoft, E. (Org. Svnth. Coll. Vol., V, 49).
To a stirred and ice-cooled solution of compound 2 ( OOg, 4.87mmol) in dry CH2C12 (30.0ml) was added neat TiCl4 (1.60ml, dl .130, 14.6mmol) followed by dichloromethyl methyl ether (Cl2CHOMe) (0.66ml, dl.211, 7.31mmol). After the addition was complete, the resultant dark green mixture was stirred at room temperature for 45 minutes. H2O (60.0ml) was added with ice-cooling, and the layers were separated. The aqueous layer was extracted with CH2C12 (20.0ml x3). The combined CH2C12 layer and extracts were washed with sat. NaCl aq. (xl), sat. NaHCO3 aq. (xl), and sat. NaCl aq., dried (MgSO4), treated with activated charcoal, and concentrated in vacuo to give a white solid. This was recrystallized from i- PrOH/f-Pr2O to give compound 3 (1.07g, 94.1 %). mp 190.8-193.2 °C; IR vm&x (nujol) 1718(s), 1709(s) cm 1 ; Η-NMR (270MHz) δ (CDC13) 10.37 (s, IH), 7.70 (s, lH), 6.43 (s, lH), 3.99 (s, 3H), 3.27 (s, 3H), 1.36 (s, 6H) ppm. Anal. % Calc for C13H15NO3: C; 66.94, H; 6.48, N; 6.00. Found: C; 66.84, H; 6.47, N; 6.04.
(iv) (2 .i5J-3-Amino-2-diphenylmethyl-l-azabicyclor2.2.21octane (Compound 4)
This compound was prepared according to the procedure (J. Med. Chem , TS, 587(1975)) (vY2 .i i-2-Diphenylmethyl-3-(6-methoxy-1.3.3-trimethyloxindol-5-yl')methylamino- l-azabicyclor2.2.21octane (Compound 5)
Reductive alkylation of compound 4 with compound 3 was carried out according to the procedures reported by Abdel-Magid, A.F., Maryanoff, C.A., and Carson, K.G. (Tetrahedron Lett.. 31, 5595 (1990)).
To a stirred solution of compound 4 (1.28g, 4.36mmol), compound 3 (1.07g, 4.58mmol) and AcOH (0.50ml, ύfl.049, 8.72mmol) in dry CH2C12 was added sodium triacetoxyborohydride (NaB(OAc)3H) (1.39g, 6.54mmol) at room temperature. The mixture was stirred at room temperature for 3.5 hours. The mixture was basified with 10% NaOH aq. (ca. 10.0ml), and the layers were separated. The aqueous layer was extracted with CH2C12 (8.0ml x3). The combined CH2C12 layer and extracts were washed with sat. NaCl aq. (xl), dried (K2CO3), and concentrated in vacuo to give a colorless glass. This was recrystallized from /-PrOH/z'-Pr2O to give compound 5 (1.89g, 85.0%) as a white powder. mp 184.7-189.1 °C; IR ^ (nujol) 1710(s), 1620(m), 1600(w), 1497(m), 1125(m), 1062(m), 830(w), 800(w), 756(w), 744(w), 706(w), 693(m) cm 1; 'H-NMR (270MHz) δ (CDC13) 7.41-7.30 (m, 2H), 7.32-7.21 (m, 2H), 7.24-7.12 (m, 5H), 6.54 (s, IH), 6.28 (s, IH), 4.49 (d, J = 12JHz, IH), 3.70 (dd, J = 12.1, 8JHz, IH), 3.61 (s, 3H), 3.61 (d, J = 12.6Hz), 3.27-3.06 (m, IH), 3.19 (s, 3H), 3.14 (d, J = 12.6Hz, IH), 2.94 (ddd, J = 3.9, 3.9, 3.9Hz, IH), 2.77 (br.dd, J = 7.5, 7.5Hz, 2H), 2.60 (br.dd, J = 11.5, 115 Hz), 2.13-2.03 (m, IH), 2.02-1.86 (m, IH), 1.75- 1.40 (m, 3H), 1.40-1.16 (m,lH), 1.32 (s, 3H), 1.31 (s, 3H) ppm. Anal. % Calc for C33H39N3O2: C; 77.77, H; 7.71, N; 8.24. Found: C; 77.62, H; 7.81, N; 8.15. (vi) (2 J-2-Diphenylmethyl-3-(6-methoxy-1.3.3-trimethyloxindol-5-yl')methylamino- l-azabicyclor2.2.21octane monobesylate (Compound 6)
After compound 5 (0.200g, 0.392mmol) was dissolved in acetone with warming, to this solution was added a solution of PhSO3H »H2O (69Jmg, 0.392mmol) in acetone. When this mixture was allowed to cool to room temperature, precipitation of white solids took place. After the mixture was left to stand in a refrigerator at 4 °C overnight, the crystals precipitated were collected by filtration, washed with ice- chilled acetone (x2), and dried in vacuo at room temperature to give compound 6 (0J98g, 75.7%) as a white powder. mp 242.7-247.7 °C (decomp.); IR Vmaι (nujol) 1713(s), 1699(s), 1620(s), 1600(m), 1500(s), 1220(s), 1175(s), 1124(s), 853(m), 820(m), 755(s), 725(s), 725(s), 707(s), 698(s) cm-1; Η-NMR (270MHz) δ (CDC13) 7.76-7.63 (m, 2H), 7.43-7.20 ( , 9H), 7.27-7.12 (m, 3H), 7.13-7.01 (m, IH), 6.52 (s, IH), 6.30 (s, IH), 4.54 (d, J = 12.1Hz, IH), 4.60-4.45 (m, IH), 3.70-3.40 (m, 4H), 3.60 (s, 3H), 3.53 (d, J = 12.3Hz, IH), 3.32-3.20 (m, IH), 3.20 (s, 3H), 3J6 (d, J = 12.3Hz, IH), 2.46-2.35 (m, IH), 2.35-2.18 ( , IH), 2.13-1.95 (m, 2H), 2.05-1.65 (m, 2H), 1.65-1.45 (m, IH), 1.31 (s, 6H) ppm. Anal. % Calc for C39H45N3O5S: C; 70.14, H; 6.79, N; 6.29. Found: C; 70.09, H; 6.88, N; 6.21.
Example 2 Preparation of (2S 5V3-(6-Methoxy-l .3.3-trimethyloxindol-5-yDmethylamino-2- phenylpiperidine dihydrochloride (Compound 13)
(i (2-? S^3-(2-Methoxybenzyl)amino-2-phenylpiperidine (Compound 7)
This compound was prepared according to the procedures disclosed in WO-93- 01170.
(ii) (25\ SH-tert-Butoxycarbonyl-3-(2-methoxybenzyl)amino-2-phenylpiperidine
(Compound 8)
To a stirred and ice-cooled mixture of compound 7 (lO.Og, 27Jmmol), 3.0M NaOH aq. (36.1ml, 108.4mmol) and tert-BuOH (15.0ml) was added (tert-BuOCO)2O (Boc^O, 7.39g, 33.8mmol) in one portion. After stirring at room temperature overnight, the mixture was extracted with AcOEt (50ml x3). The combined AcOEt extracts were washed with H2O (x3), and sat. NaCl (xl), dried (Na2SO4), and concentrated in vacuo to give compound 8 (11.27g, quant.) as a pale yellow syrup. IR Vmx (film) 3350(w), 1693(s), 1605(s), 1590(m), 1492(s), 755(m) cm"1; 'H-
NMR (270MHz) δ (CDC13) 7.58 (br.d, J = 7.3Hz, 2H), 7.36-7.16 (m, 5H), 6.89 (ddd, J = 7.5, 7.5, 1.1Hz, IH), 6.81 (dd, J = 8.4, 0.8Hz, IH), 5.47 (br.s, IH), 3.96 (dm, J = 13.4Hz, IH), 3.87 (d, J = 13.6Hz, IH), 3.79 (d, J = 13.6Hz, IH), 3.70 (s, 3H), 3J0-2.99 (m, IH), 2.94 (dd, J = 12.5, 3.4Hz, IH), 1.87-1.74 (m, 2H), 1.74-1.40 (m, 3H), 1.41 (s, 9H) ppm.
This was employed in the next step without further purification. (iii) (2 ' 5i-3-Amino-l-tgrt-butoxycarbonyl-2-phenylpiperidine (Compound 9)
A mixture of compound 8 (11.27g), 20% Pd(OH)2 / C (Pearlman's catalyst, 3J0g), and MeOH (90ml) was stirred under an atmosphere of H2 (balloon) at room temperature overnight. After an additional amount of 20% Pd(OH)2 / C (0.55g) was added, the stirring was continued under an atmosphere of H2 (balloon) at room temperature for three days. The catalyst was filtered off by the aid of celite, and washed with MeOH thoroughly. The combined MeOH filtrate and washings were concentrated in vacuo to give crude compound 9 (8.59g, quant.). This was dissolved in EtOH (20.0ml), and then a warmed solution of fumaric acid (1.57g, 13.5mmol) in EtOH (20.0ml)was added in one portion to this solution at room temperature. When the mixture was scratched with a spatula, there took place precipitation of white solids with ease. After the mixture was left to stand at 4 °C in a refrigerator overnight, the crystals precipitated were collected by filtration, washed with ice-chilled EtOH (xl), and dried in vacuo at 50 °C to give a first crop of (2S,3S)- 3-amino-l-(tert-butoxycarbonyl)-2-phenylpiperidinesemifumaratecompoundlO(6J4g, 67.8%) as white short needles. The combined filtrate and washing were concentrated in vacuo to give a residual solid (4.56g), which was recrystallized from EtOH and i- Pr2O to give a second crop of compound 10 (1.25g, 13.7%). mp 165.7-168.8 °C; Anal. % Calc for C18H26N2O4 -0.4H2O: C; 63.29, H; 7.91 , N; 8.20. Found: C; 63.64, H; 8.22, N; 7.79. After a suspension of compound 10 (1.24g, 3.7 Immol) in H2O was ice-cooled, 20% NaOH aq. was added until the mixture became basic. The mixture was then extracted with AcOEt (x3). The combined AcOEt extracts were washed with sat. NaCl aq. (xl), dried (Na2SO4), and concentrated in vacuo to give pure compound 9 (0.95g, 93.1 %).
IR j>max (film) 3370(w), 3310(w), 1695(s), 1682(s), 1807(m), 1590(w, shoulder), 1494(s), 1250(s), 1180(s), 1150(s), 756(m), 703(s) cm 1; Η-NMR (270MHz) δ
(CDC13) 7.47-7.39 (m, 2H), 7.37-7.23 (m, 5H), 5J9 (br.d, J = 6.2Hz, IH), 4.00
(dm, J = 13.0Hz, IH), 3.25-3.05 (m, 2H), 1.94-1.83 (m, IH), 1.83-1.56 (m, 4H),
1.36 (s, 9H), 1.32 (br.s, 2H) ppm.
(iv) (2S. 3S) -l-ten -Butoxycarbonyl-3-(6-methoxy-1.3.3-trimethyloxindol-5-yl) methylamino-2-phenylpiperidine (Compound 11)
Reductive alkylation of compound 9 with compound 3 was carried out according to the procedures reported by Abdel-Magid, A.F., Maryanoff, C.A., and Carson, K.G. (Tetrahedron Lett.. 31, 5595 (1990)).
To a stirred and ice-cooled solution of compound 9 (0.504g, 1.82mmol) and compound 3 (0.468g, 2.01mmol) in dry CH2C12 (17.0ml) was added NaB(OAc)3H
(0.579g, 2.73mmol) in one portion. After the mixture was stirred at room temperature for eight hours, NaB(OAc)3H (0.30g, 1.42mmol) and AcOH (0J04ml, l .049,
1.82mmol) were added, and the stirring was continued at room temperature for additional three nights. The mixture was basified to pH9-10 with 10% NaOH aq. (9.0ml), and the layers were separated. The aqueous layer was extracted with CH2C12
(x3). The combined CH2C12 layer and extracts were washed with NaCl aq. (xl), dried
(K2CO3), and concentrated in vacuo to give a colorless syrup (1.06g). This was flash- chromatographed over silica gel (Merck Kieselgel 60, 30g). Elution with CH2C12-
MeOH (200:1-150:1-100:1) gave compound 11 (0.644g, 71.9%) as a colorless syrup. IR » (film) 3345(w), 1715(s), 1695(s), 1681(s), 1625(s), 1604(s), 1508(s),
886(m), 820(m), 732(s), 703(s) cm"1; 'H-NMR (270MHz) δ (CDC13) 7.60 (br.d, J =
7.0Hz, 2H), 7.38-7.23 (m, 3H), 7.00 (s, IH), 6.36 (s, IH), 5.57-5.45 (m, IH), 4.03- 3.89 (m, IH), 3.84 (d, J = 12.8Hz, IH), 3.78 (d, J = 12.8Hz, IH), 3.74 (s,3H), 3.20 (s, 3H), 3.11-2.90 (m, 2H), 1.90-1.74 (m,2H), 1.74-1.45 (m, 3H), 1.41 (s, 9H), 1.32 (s, 3H), 1.31 (s, 3H) ppm.
(vY2 )-3-(6-Methoxy-1.3.3-trimethyloxindol-5-yl)methylamino-2-phenylpiperidine (Compound 12)
To a stirred and ice-cooled solution of compound 11 (0.64g, 1.3 Immol) in AcOEt (5.0ml) was added cone. HCl (2.0ml) dropwise. The mixture was stirred at room temperature for 45 minutes. The mixture was ice-cooled, and then basified with 20% NaOH aq. (ca. 8.0ml). The layers were separated, and the aqueous layer was extracted with AcOEt (x3). The combined AcOEt layer and extracts were washed with sat. NaCl aq. (xl), dried (K2CO3), and concentrated in vacuo to give compound 12 (0.48g, 93.6%) as a colorless syrup.
IR ^(film) 3330(m), 1710(s), 1620(s), 1600(s), 1500(s), 1250(s), 1125(s), 1060(m) cm 1; 'H-NMR (270MHz) δ (CDC13) 7.38-7.17 (m, 5H), 6.79 (s, IH), 6.24 (s, IH), 3.90 (d, J = 2.4Hz, IH), 3.63 (d, J = 13.7Hz, IH), 3.54 (s, 3H), 3.40 (d, J = 13.7Hz, IH), 3.31-3.21 (m, IH), 3.17 (s, 3H), 2.85 (ddd, J = 2.4, 2.4, 2.4Hz, IH), 2.80 (ddd, J = 12.6, 12.6, 3.1Hz, IH), 2.14 (dm, J = 12.6Hz, IH), 1.93 (ddddd, J = 12.6, 12.6, 12.6, 4.0, 4.0Hz, IH), 1.69 (br.s, 2H), 1.61 (dddd, J = 12.6, 12.6, 3.7, 3.7Hz, IH), 1.42 (dm, J = 12.6Hz, IH), 1.29 (s, 3H), 1.28 (s, 3H) ppm.
This was employed in the next salt formation step without further purification. (vi) (2S. J )-3-(6-Methoxy- 1.3.3-trimethyloxindol-5-yl)methylamino-2-phenylpiperidine dihydrochloride (Compound 13)
To a solution of compound 12 (0.48g, 1.22mmol) in MeOH (0.5ml) was added an excess amount of Hydrogen Chloride, Methanol Reagent 10 (Tokyo Kasei, 6.0ml). After the solvent MeOH was evaporated in vacuo, the residual solid was recrystallized from MeOH-Et2O. The recrystallization mixture was left to stand at 4 °C in a refrigerator for three nights. The crystals precipitated were collected by filtration, washed with Et2O (x2), and dried in vacuo at 50 °C to give compound 13 (0.401g, 70.4%) as a white powder. mp 223.7 - 239.7 °C; IR ^max(nujol) 2900-2200(br. , s), 1718(s), 1710(s), 1630(s), 1605(m), 1565(s), 1505(s), 1250(s), 1180(s), 1129(s), 1060(m), 900(m), 850(m), 824(m), 765(m), 750(s), 692(s) cm 1. Anal. % Calc for C24H33N3O2Cl2: C; 61.80, H; 7.13, N; 9.01. Found: C; 61.67, H; 7.13, N; 9.00.
Example 3 Preparation of (25. JSJ-2-Diphenylmethyl-3-(6-methoxy-l-methyl-2-oxo-l .2.3.4- tetrahydroquinolin-7-yl)methylamino-l-azabicyclor2.2.21octane (Compound 17) (i) 6-Methoxy-l-methyl-2-oxo-1.2-dihydroquinoline (Compound 14)
Preparation of compound 14 from 6-methoxyquinoline was carried out according to the procedures disclosed in EP 385662.
A mixture of 6-methoxyquinoline (16 g, 100 mmol) and dimethyl sulfate (13 g, 100 mmol) and in benzene (50 ml) was refluxed for 1 hr. After the reaction mixture was cooled down to room temperature, the orange solution was decanted off. The resulting salt was washed with benzene (30 ml x 3). This salt was dissolved in H2O (50 ml) and the solution was washed with benzene (30 ml). This solution and a solution of NaOH (12 g, 300 mmol) in H2O (50 mL) were added to a mixture of potassium ferricyanide (66 g, 200 mmol) in H2O and CH2C12 at room temperature over 15 min.
The resulting mixture was stirred at room temperature for 15hr. The organic layer was separated and the aqueous layer was extracted with CH2C12 (150 ml) three times.
The combined extracts were dried over Na2SO4 and concentrated. The crude was purified by recrystallization from AcOEt-hexane to give compound 14 (12 g, 63 mmol, 63%) as a pale yellow crystal.
'H-NMR (270MHz) δ (CDC13) 7.70-6.70 (m, 5H), 3.88 (s, 3H), 3.72 (s, 3H) ppm. (ii) 6-Methoxy-l-methyl-2-oxo-1.2.3.4-tetrahydroquinoline (Compound 15)
A mixture of compound 14 (3.0 g, 16 mmol), 10 % Pd-C (0.7 g) and EtOH (20 ml) was heated in an autoclave at 100°C under 50 atm of H2 for 15hr. The catalyst was removed by filtration and the filtrate was concentrated in vacuo to give a crude solid. This was purified by recrystallization from MeOH to give compound 15 (1.8 g, 9.4 mmol, 53%) as a colorless crystal.
'H-NMR (270 MHz) δ (CDC13) 6.96-6.68 (m, 3H), 3.79 (s, 3H), 3.33 (s, 3H), 2.95-2.56 (m, 4H) ppm.
(iii) 6-Methoxy- 1 -methyl-2-oxo- 1.2.3.4-tetrahydroquinoline-7-carboxaldehyde
(Compound 16) This compound was prepared from compound 15 in the same manner of compound 3
Η-NMR (270 MHz) δ (CDC13) 10.44 (s, IH), 7.42 (s, IH), 6.84 (s, IH), 3.94 (s, 3H), 3.37 (s, 3H), 2.97 (t, 2H, J = 7Hz), 2.66 (t, 2H, J = 7Hz) (iv) (2S.JS)-2-Diphenylmethyl-3-(6-methoxy-l -methyl-2-oxo-1.2.3.4- tetrahydroquinolin-7-yl)methylarnino-l-azabicyclor2.2.21octane (Compound 17)
This compound was prepared from compound 16 and compound 4 in the same manner of compound 5 mp 136 - 139 °C. Η-NMR (270 MHz) δ (CDC13) 7.38-6.43 (m, 12H), 4.47 (d, J = 12 Hz, IH), 3.75-2.55 (m, 13H), 3.54 (s, 3H), 3.27 (s, 3H), 2.16-1.20 (m, 4H) ppm. Anal. Calc for C32H37N3O2 -0.25H2O: C; 76.84 % , H; 7.56 %, N; 8.40 %. Found: C; 76.81 %, H; 7.45 % , N, 8.41 % .
Example 4 Preparation of (2S.3S) - 2 - Diphenylmethyl-3-(6-methoxy-l-methyl-2-oxo-1.2- dihydroquinolin-7-yl)methylamino-l-azabicyclo[2.2.2"loctane (Compound 19)
(i) 6-Methoxy-l-methyl-2-oxo-l .2-dihydroquinoline-7-carboxaldehyde (Compound 18) A mixture of compound 16 (2.0 g, 9.0 mmol), DDQ (9.0 g, 40 mmol) and dioxane (100 ml) was stirred and heated at 140 °C for two days. After the reaction mixture was cooled down to room temperature, the mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by a column chromatography on silicagel to give a pale yellow solid, which was recrystallized to give compound 18 (0.7 g, 31 mmol, 35%) as a pale yellow crystal.
'H-NMR (270 MHz) δ (CDC13) 10.57 (s, IH), 7.84 (s, IH), 7.64 (d, J = 10 Hz, IH), 7J0 (s, IH), 6.84 (d, J = 10 Hz, IH), 4.00 (s, 3H), 3.75 (s, 3H) ppm. (ii) (2 '.i5J-2-Diphenylmethyl-3-(6-methoxy-l-methyl-2-oxo-1.2-dihydroquinolin-7- yl)methylamino-l-azabicyclo|2.2.2]octane (Compound 19)
This compound was prepared from compound 18 and compound 4 in the same manner of compound 5 mp 125 - 128 °C. 'H-NMR (270 MHz) δ (CDC13) 7.61-6.63 (m, 14H), 4.47 (d, J = 12 Hz, IH), 3.72-2.55 (m, 9H), 3.66 (s, 3H), 3.62 (s, 3H), 2.14-1.20 (m, 4H) ppm. Anal. Calc for C32H35N3O2 -0.5H2O -0.4(2-propanol): C; 75.71 %, H; 7.50 %, N; 7.98 %. Found: C; 75.41 %, H; 7.50 % , N; 7.91 %. Example 5 Preparation of (2 tS'J-3-(6-methoxy-l-methyl-2-oxo-l .2.3.4-tetrahydroquinolin-7- yl)methylamino-2-phenylpiperidine dihydrochloride (Compound 21) (i) ι 5'..?,S'J-2-Phenylpiperidin-3-amine dihydrochloride (Compound 20) This compound was prepared according to the procedures disclosed in EP-
558156.
(ii) (2- '.i )-3-(6-Methoxy-l-methyl-2-oxo-1.2.3.4-tetrahvdroquinolin-7- yl)methylamino-2-phenylpiperidine dihydrochloride (Compound 21)
A mixture of compound 20 (250 mg, 1 mmol), compound 16 (220 mg, 1 mmol) and sodium triacetoxyborohydride (400 mg, 1.9 mmol) in CH2C12 (10 ml) was stirred at room temperature for 24hr., quenched with NaHCO3 aq , and extracted with CH2C12 three times. The combined extracts were dried over Na2SO4 and concentrated. The crude was purified by a column chromatography on silicagel to give a free base of compound 21. This was derived to dihydrochloride salt with HCl-MeOH, which was washed with IPA to give compound 21 (100 mg, 0.22 mmol, 22%) as a colorless crystal. mp 265 - 268 °C. IR * (KBr) 3415, 2935, 1673, 1647, 1556, 1513, 1469,
1452, 1430, 1366, 1249, 1185, 1163, 1065, 1027 cm '. 'H-NMR (270 MHz) δ (free base; CDC13) 7.43-6.52 ( , 7H), 4.00-3.28 (m, 4H), 3.51 (s, 3H), 3.22 (s, 3H), 2.96- 1.45 (m, 10H) ppm. Anal.. Calc for C23H29N3O2 - 2HC1 -0.5H2O: C; 59.87 %, H, 6.99
%, N, 9.11 %. Found: C; 59.82%, H; 7.37 %, N, 9.23 %.
The compound obtained was subjected to the IM-9 binding assay, the [Sar9, Met(O2)"]substance P-induced tapping test and the verapamil binding study as described before, with the results of less than OJnM, 52% (% inhibition at 0.3mg/kg scoring) and more than 3000nM, respectively.
Example 6 Preparation of (2S ')-3-(6-Isopropoxy-l-methyl-2-oxo-l ,2.3.4-tetrahydroquinolin-7- yl)methylamino-2-phenylpiperidine dihydrochloride (Compound 26) (i) 6-Hydroxy-l-methyl-2-oxo-1.2.3.4-tetrahydroquinoline (Compound 22) To a stirred solution of compound 15 (500 mg, 2.61 mmol) in CH2C12 (7 ml) was added BBr3 (1.0 M in CH2C12, 5.74 ml, 5.74 mmol) at room temparature, and stirred for 3h. The mixture was poured into ice water. The aqueous layer was extracted with AcOEt (x 2). The combined organic layers were washed with sat. NaCl aq, dried (MgSO4), filtered, and concentrated to give compound 22 (350 mg, 76%) as a colorless crystal.
'H-NMR (270MHz) δ (CDC13) 6.85 (IH, d, J = 8.4 Hz), 6.75-6.70 (m, 2H), 3.34 (3H, s), 2.86 (2H, t, J = 7.1 Hz), 2.63 (2H, t, J = 7.1 Hz) ppm. (ii) 6-Isopropoxy-l-methyl-2-oxo-1.2.3.4-tetrahydroquinoline (Compound 23)
To a stirred solution of compound 22 (350 mg, 1.98 mmol) and 2-iodopropane (0.590 ml, 5.93 mmol) in acetone (16 ml) was added Cs2CO3 (2.90 g, 8.91 mmol), and heated at 55 °C for 3h. The mixture was filtered over celite and washed with acetone. The filtrate was concentrated to give crude compound 23. This was diluted with AcOEt, washed with water and sat. NaCl aq, dried (MgSO4), and concentrated. This was purified by SiO2 chromatography to give compound 23 (382 mg, 88%) as a colorless oil.
'H-NMR (270MHz) δ (CDC13) 6.88 (IH, d, J = 8.4 Hz), 6.80-6.70 (m, 2H), 4.49 (IH, hep, J = 5.9 Hz), 3.33 (3H, s), 2.86 (2H, t, J = 7.2 Hz), 2.66-2.59 (2H, m), 1.33 (6H, d, J = 5.9 Hz) ppm.
(iii) 6-Isopropoxy -1- methyl-2-oxo-1.2.3.4-tetrahydroquinoline-7-carboxaldehyde (Compound 24)
To a stirred solution of compound 23 (382 mg, 1.74 mmol) in CH2C12 (10 ml) was added TiCl4 (0.42 ml, 3.83 mmol) at -20°C. After the reaction mixture was stirred for 10 minutes, Cl2CHOMe (0.35 ml, 3.83 mmol) was added at -20°C; and stirred for 2h. After H2O was added, the mixture was extracted with CH2C12 (x 3). The combined extracts were dried (MgSO4), filtered, and concentrated. The residue was purified by SiO2 chromatography to give compound 24 (391 mg, 91 %) as a slight yellow crystal.
'H-NMR (270 MHz) δ (CDC13) 10.44 (IH, s), 7.41 (IH, s), 6.84 (IH, s), 4.65 (IH, hep, J = 5.9 Hz), 3.36 (3H, s), 2.94 (2H, t, J = 7.3 Hz), 2.66 (2H, t, J = 7.3 Hz), 1.40 (6H, ά, J = 5.9 Hz) ppm.
(iv) (2S.3S)- 1 -tgrt-Butoxycarbonyl-3-(6-isopropoxy- 1 -methyl-2-oxo- 1.2.3.4- tetrahydroquinolin-7-yl)methylamino-2-phenylpiperidine (Compound 25)
A mixture of compound 9 (436 mg, 1.58 mmol), compound 24 (390 mg, 1.58 mmol), sodium triacetoxyborohydride (670 mg, 3J6 mmol) and CH2C12 (8 ml) was stirred under nitrogen at room temperature for 2h. After NaHCO3 aq. solution was added, the mixture was extracted with CH2C12 (x 3). The combined extracts were dried (MgSO4), filtered and concentrated. This was purified by SiO2 chromatography to give compound 25 (698 mg, 87%) as a colorless oil. 'H-NMR (270 MHz) δ (CDC13) 7.58 (2H, d, J = 7.0 Hz), 7.37-7.22 (3H, m),
6.88 (IH, s), 6.64 (IH, s), 5.54-5.42 (IH, m), 4.45 (IH, hep, J = 5.9 Hz), 4.02- 3.78 (3H, m), 3.30 (3H,s), 3.12-2.92 (2H, m), 2.83 (2H, t, J = 7.3 Hz), 2.61 (2H, t, J = 7.3 Hz), 1.95-1.30 (4H, m), 1.40 (9H, s), 1.26 (3H, d, J = 5.9 Hz), 1.24 (3H, d, J = 5.9 Hz) ppm. (v) (2 )-3-(6-Isopropoxy-l-methyl-2-oxo-1.2.3.4-tetrahydro-quinolin-7-yl)methyl amino-2-phenylpiperidine dihydrochloride (Compound 26)
To a solution of compound 25 (312 mg, 0.615 mmol) in AcOEt (6 ml) was added an excess amount of Hydrogen Chloride, Methanol Reagent 10 (Tokyo Kasei, 3 ml). The mixture was stirred for 4 h and then evaporated in vacuo, the residual solid was recrystallized from MeOH-Et2O to give compound 26 (140 mg, 47%) as a white crystal. mp 249-251 °C; 'H-NMR (270 MHz) δ (free base; CDC13) 7.40-7.18 (5H, m), 6.63 (IH, s), 6.55 (IH, s), 4.31 (IH, hep, J = 6.2 Hz), 3.89 (IH, d, J = 2.2 Hz), 3.54 (IH, d, J = 13.7 Hz), 3.41 (IH, d, J = 13.7 Hz), 3.42-3.20 (IH, m), 3.20 (3H,s), 2.95-2.75 (4H, m), 2.64-2.55 (2H, m) 2.22-2.10 (IH, m), 1.98-1.82 (IH, ), 1.72-1.56 (IH, m), 1.52-1.39 (IH, m), 1.15 (3H, d, J = 5.9 Hz), 1.12 (3H, d, J = 5.9 Hz) ppm. IR »>max (KBr) 3420, 2915, 2650, 2460, 1666, 1513, 1468, 1436, 1404, 1372, 1130, 964 cm '. Anal, calcd for C25H35N3O2Cl2: C; 62.50%, H; 7.34%; N 8.75% ; Found: C; 62.12%, H; 7.58%, N; 9.04% . Example 7
Preparation of (2 .i5 -3-(6-Methoxy-l-methyl-2-oxo-l .2-dihydroquinolin-7- yl)methylamino-2-phenylpiperidine dihydrochloride (Compound 28) (iϊ2 '.i5r)-l-tgrt-Butoxycarbonyl-3-(6-methoxy-l-methyl-2-oxo-1.2-dihydroquinolin-7- yl)methylamino-2-phenylpiperidine (Compound 27) This compound was prepared from compound 18 and compound 9 in the same manner of compound 11.
'H-NMR (270 MHz) δ (CDC13) 7.70 - 6.66 (9H, m), 5.52 (IH, br), 4.10 - 3.62 (3H, m), 3.77 (3H,s), 3.68 (3H,s), 3.30 - 2.92 (2H, ), 2.10 - 1.30 (4H, ), 1.40 (9H, s) ppm.
This was employed in the next step without further purification. (ii) (25' 5'J-3-(6-Methoxy-l-methyl-2-oxo-1.2-dihvdroαuinolin-7-yl)methylamino-2- phenylpiperidine dihydrochloride (Compound 28)
This compound was prepared from compound 26 in the same manner of compound 12. mp 260 - 263 °C. 'H-NMR (270 MHz) δ (free base; CDC13) 7.60 - 6.62 (9H, m), 3.95 - 2.75 (6H, m), 3.61 (3H,s), 3.54 (3H,s), 2.23 - 1.42 (4H, m) ppm. Anal.. Calc for C23H27N3O2 • 2HC1 • H2O: C; 58.98 % , H, 6.67 % , N, 8.97 % . Found: C; 58.71 %, H; 6.97 %, N, 8.72 % .
Example 8 Preparation of (25.3 ^-3-(l-Isopropyl-6-methoxy-2-oxo-l .2.3.4-tetrahydroquinolin-7- yl)methylamino-2-phenylpiperidine dihydrochloride (Compound 33) (i) 6-Methoxy-2-oxo-1.2.3.4-tetrahydroquinoline (Compound 29)
This compound was prepared according to the procedure (J. Med. Chem. 30. 295(1987)). (ii) l-Isopropyl-6-methoxy-2-oxo-1.2.3.4-tetrahydroquinoline (Compound 30)
To a stirred solution of compound 29 (560 mg, 3.0 mmol) and 2-iodopropane (1.0 g, 6.0 mmol) in DMF (5 ml) was added NaH (240 mg, 6.0 mmol), and heated at 60 °C for 3 h. The mixture was diluted with water, extracted with CH2C12 (50 ml) three times. The combined extracts were dried over Na2SO4 and concentrated. The crude product was purified by a column chromatography on silicagel to give compound 30 (290 mg, 1.3 mmol, 44%) as a pale yellow crystal. 'H-NMR (270 MHz) δ (CDC13) 7.10-6.70 (m, 3H), 4.68 (hep, IH, J = 7Hz),
3.79 (s, 3H), 2.84-2.50 (m, 4H), 1.50 (d, 6H, J = 7Hz) ppm. (iii) l-Isopropyl-6-methoxy-2-oxo-1.2.3.4-tetrahydroquinoline-7-carboxaldehyde
(Compound 31)
This compound was prepared from compound 30 in the same manner of compound 3
'H-NMR (270 MHz) δ (CDC13) 10.43 (s, IH), 7.57 (s, IH), 6.82 (s, IH), 4.67 (hep, IH, J = 7Hz), 3.93 (s, 3H), 2.87 (t, 2H, J = 7Hz), 2.57 (t, 2H, J = 7Hz), 1.51 (d, 6H, 7 = 7Hz) ppm.
(iv) (25\i5Vl-t -Butoxycarbonyl-3-(l-isopropyl-6-methoxy-2-oxo-1.2.3.4- tetrahydroquinolin-7-yl)methylamino-2-phenylpiperidine (Compound 32)
This compound was prepared from compound 31 and compound 9 in the same manner of compound 11.
'H-NMR (270 MHz) δ (CDC13) 7.65 - 6.60 (7H, m), 5.48 (IH, br), 4.62 (IH, hep, 7 = 7 Hz), 4.03 - 3.75 (3H, m), 3.70 (3H, s), 3J4 - 2.48 (6H, m), 1.95 - 1.40 (4H, m), 1.48 (3H, d, 7 = 7 Hz), 1.47 (3H, d, 7 = 7 Hz), 1.40 (9H, s) ppm. This was employed in the next step without further purification. (v) (25. 5)-3-(l-Isopropyl-6-methoxy-2-oxo-1.2.3.4-tetrahvdroquinolin-7- yl)methylamino-2-phenylpiperidine dihydrochloride (Compound 33)
This compound was prepared from compound 32 in the same manner of compound 12. mp 257 - 260 °C. IR vw (KBr) 3440, 2960, 2925, 1665, 1554, 1506, 1464, 1455, 1435, 1412, 1372, 1355, 1326, 1316, 1234, 1196, 1141, 1033 cm"'. 'H-NMR (270 MHz) δ (free base; CDC13) 7.40 - 6.50 (7H, m), 4.55 (IH, hep, 7 = 7 Hz), 3.94 - 3.22 (4H, m), 3.49 (3H,s), 2.90 - 2.47 (6H, m), 2.20 - 1.38 (4H, m), 1.46 (3H, d, 7 = 7 Hz), 1.46 (3H, d, 7 = 7 Hz) ppm. Anal. Calc for C25H33N3O2 -2HCl - H2O: C; 60.24 %, H, 7.48 %, N, 8.43 %. Found: C; 60.46% , H; 7.77 %, N, 8.13 %.
Example 9 Preparation of (25. JS)-3-r(6-Difluoromethoxy- l-methyl-2-oxo- l .2.3.4- tetrahydroquinolin-7-yl)methynamino-2-phenylpiperidine dihydrochloride (Compound
(i) 6-Hydroxy- 1 -methyl-2-oxo- 1.2.3.4-tetrahydroquinoline-7-carboxaldehyde
(Compound 34)
This compound was prepared from compound 16 in the same manner of compound 22.
'H-NMR (270MHz) δ (CDC13) 10.89 (IH, s), 9.88 (IH, s), 7.07 (IH, s), 6.85 (IH, s), 3.39 (3H, s), 2.98-2.88 (2H, m), 2.68-2.58 (2H, m) ppm.
(ii) 6-Difluoromethoxy-l-methyl-2-oxo-1.2.3.4-tetrahydroquinoline-7-carboxaldehyde (Compound 35) To a stiπed solution of compound 34 (160 mg, 0.78 mmol) and NaOH (200 mg, 5.0 mmol) in dioxane - H2O (10 ml) was bubbled C1CHF2 at 100 °C for 18 h. The solvent was removed by evaporation, and the residue was diluted with CH2C12. This was washed with water and brine, dried over MgSO4, filtered, and concentrated. The crude product was purified by a column chromatography on silicagel to give compound 35 (20 mg, 0.078 mmol, 10 %) as a white solid.
'H-NMR (270MHz) δ (CDC13) 10.34 (IH, s), 7.49 (IH, s), 7.11 (IH, s), 6.64 (IH, t, 7 = 72.5 Hz), 3.40 (3H, s), 3.05 - 2.95 (2H, m), 2.73 -2.63 (2H, ) ppm. (iii) 2S.3S)- 1 -tgrt-Butoxycarbon yl-3-r(6-difluoromethoxy- 1 -methyl-2-oxo- 1.2.3.4- tetrahydroquinolin-7-yl)methyllamino-2-phenylpiperidine (Compound 36)
This compound was prepared from compound 35 and compound 9 in the same manner of compound 11.
'H-NMR (270 MHz) δ (CDC13) 7.62 - 7.53 (2H, m), 7.38 - 7.23 (3H, ), 6.95 - 6.91 (2H, ), 6.42 (IH, t, 7 = 74.4 Hz), 5.52 - 5.43 (IH, m), 4.02 - 3.88 (3H, ), 3.29 (3H, s), 3.12 - 2.94 (2H, m), 2.90 - 2.82 (2H, m), 2.67 - 2.58 (2H, m), 2.00 - 1.40 (4H, m), 1.40 (9H, s) ppm.
(iv) (2 S)-3-r(6-Difluoromethoxy-l-methyl-2-oxo-1.2.3.4-tetrahvdroquinolin-7- yl)methyllamino-2-phenylpiperidine dihydrochloride (Compound 37)
This compound was prepared from compound 36 in the same manner of compound 12. mp 238 - 240 °C. IR ^ (KBr) 3440, 2930, 2763, 2475, 1681, 1521 , 1431 , 1116, 1044 cm '. 'H-NMR (270 MHz) δ (free base; CDC13) 7.42 - 7.22 (5H, m), 6.83 (IH, s), 6.75 (IH, s), 6.25 (IH, t, 7 = 74.3 Hz), 4.03 - 3.98 (IH, m), 3.62 (IH, d, 7 = 13.9 Hz), 3.42 - 3.33, (IH, m), 3.38 (IH, d, 7 = 13.9 Hz), 3J9 (3H, s), 2.98 - 2.76 (4H, m), 2.65 - 2.55 (2H, m), 2.20 - 1.50 (4H, m) ppm. Anal. Calc for C23H27F2N3O2 - 2HCl: C; 56.56 %, H, 5.98 %, N, 8.60 %. Found: C; 56.28 %, H; 6.05 %, N, 8.39 %.
Example 10 Preparation of (2S. JS)-3-rr6-Methoxy- 1 -(2.2.2-trifluoroethyl)-2-oxo- 1.2.3.4- tetrahydroquinolin-7-yl1methynamino-2-phenylpiperidine dihydrochloride (Compound 41} (i) 6-Methoxy- 1 -(2.2.2-trifluoroethyl)-2-oxo- 1.2.3.4-tetrahvdroquinoline(Compound 38}
This compound was prepared from compound 29 and CH3SO3CH2CF3 in the same manner of compound 30.
'H-NMR (270MHz) δ (CDC13) 6.98 (IH, d, 7 = 8.4 Hz), 6.80 - 6.72 (2H, m), 4.61 (2H, q, 7 = 8.4 Hz), 3.80 (3H, s), 2.95 - 2.87 (2H, m), 2.75 - 2.67 (2H, ) ppm.
(ii) 6-Methoxy-l-(2.2.2-trifluoroethyl)-2-oxo-1.2.3.4-tetrahydroquinoline-7- carboxaldehyde (Compound 39)
This compound was prepared from compound 38 in the same manner of compound 3
•H-NMR (270MHz) δ (CDC13) 10.43 (IH, s), 7.53 (IH, s), 6.86 (IH, s), 4.68 (2H, q, 7 = 8.4 Hz), 3.95 (3H, s), 3.05 - 2.96 (2H, m), 2.78 - 2.69 (2H, m) ppm. (iii) (2 '.i5)-l-tgrt-Butoxycarbonyl-3-rr6-methoxy-l-(2.2.2-trifluoroethyl)-2-oxo- 1.2.3.4-tetrahydroquinolin-7-yl]methyllamino-2-phenylpiperidine (Compound 40) This compound was prepared from compound 39 and compound 9 in the same manner of compound 11.
'H-NMR (270MHz) δ (CDC13) 7.60 - 7.50 (2H, m), 7.35 - 7.18 (3H, m), 6.98 (IH, s), 6.63 (IH, s), 5.53 - 5.38 (IH, m), 4.70 - 4.50 (2H, m), 3.98 - 3.70 (3H, m), 3.72 (3H, s), 3.08 - 2.80 (4H, m), 2.70 - 2.62 (2H, ), 1.90 - 1.40 (4H, m), 1.39 (9H, s) ppm.
(iv) (2- .i^-3-rr6-Methoxy-l-(2.2.2-trifluoroethyl)-2-oxo-1.2.3.4-tetrahvdroquinolin-7- yπmethyllamino-2-phenylpiperidine dihydrochloride (Compound 41)
This compound was prepared from compound 40 in the same manner of compound 12. mp 243 - 245 °C. IR * (KBr) 3450, 2940, 2785, 2700, 1679, 1578, 1427,
1260, 1169, 1154, 1037 cm '. 'H-NMR (270 MHz) δ (free base; CDC13) 7.42 - 7.22 (5H, m), 6.87 (IH, s), 6.53 (IH, s), 4.82 - 4.48 (2H, m), 3.95 (IH, d, 7 = 2.2 Hz), 3.65 (IH, 7 = 14.3 Hz), 3.54 (3H, s), 3.41 (IH, d, 7 = 14.3 Hz), 3.40 - 3.30 (IH, m), 2.95 - 2.80 (4H, m), 2.72 - 2.62 (2H, m), 2.20 -1.95 (2H, m), 1.73 - 1.45 (2H, m) ppm. Anal. Calc for C24H28F3N3O2 • 2HC1: C; 55.39 %, H, 5.81 %, N, 8.07 %. Found: C; 55.05 %, H; 5.87 %, N, 8.08 %.
Example 11 Preparation of (2 .35i-3-rπ-Methyl-6-(2.2.2-trifluoroethoxy)-2-oxo-l .2.3.4- tetrahydroquinolin-7-yllmethyl1amino-2-phenylpiperidine dihydrochloride (Compound 45}
(i) l-Methyl-6-(2.2.2-trifluoroethoxy)-2-oxo-1.2.3.4-tetrahydroquinoline(Compound 42}
This compound was prepared from compound 21 and CH3SO3CH2CF3 in the same manner of compound 23.
'H-NMR (270MHz) δ (CDC13) 6.95 - 6.78 (3H, m), 4.33 (2H, q, 7 = 8.1 Hz), 3.34 (3H, s), 2.93 - 2.84 (2H, m), 2.68 - 2.59 (2H, m) ppm. (ji} l-Methyl-6-(2.2.2-trifluoroethoxy)-2-oxo-1.2.3.4-tetrahydroquinoline-7- carboxaldehyde (Compound 43)
This compound was prepared from compound 42 in the same manner of compound 3
This was employed in the next step without further purification. (iii) (2S.3S)- 1 -tgrt-Butoxycarbonyl-3-πJ -methyl-6-(2.2.2-trifluoroethoxy)-2-oxo- 1.2.3.4-tetrahydroquinolin-7-yl"|methyl1amino-2-phenylpiperidine (Compound 44)
This compound was prepared from compound 43 and compound 9 in the same manner of compound 11.
'H-NMR (270MHz) δ (CDC13) 7.64 - 7.52 (2H, m), 7.36 - 7.22 (3H, ), 6.91 (IH, s), 6.63 (IH, s), 5.52 - 5.42 (IH, m), 4.29 (2H, q, 7 = 8.4 Hz), 4.02 - 3.90 (IH, m), 3.93 - 3.78 (2H, m), 3.29 (3H, s), 3.12 - 2.88 (2H, m), 2.90 - 2.80 (2H, m), 2.67 - 2.57 (2H, m), 1.98 - 1.50 (4H, m), 1.40 (9H, s) ppm. (iv) (25,.i )-3-rri-Methyl-6-(2.2.2-trifluoroethoxy)-2-oxo-1.2.3.4-tetrahvdroquinolin-7- yrimethyπamino-2-phenylpiperidine dihydrochloride (Compound 45) This compound was prepared from compound 44 in the same manner of compound 12. mp 239 - 240 °C. IR » (KBr) 3440, 2955, 2775, 1650, 1520, 1471, 1454, 1292, 1245, 1158 cm"'. 'H-NMR (270 MHz) δ (free base; CDC13) 7.38 - 7.20 (5H, m), 6.67 (IH, s), 6.55 (IH, s), 4.13 (2H, q, 7 = 8.4 Hz), 3.95 (IH, d, 7 = 1.8 Hz), 3.60 (IH, 7 = 14.3 Hz), 3.41 (IH, d, 7 = 14.3 Hz), 3.38 - 3.27 (IH, m), 3.19 (3H, s), 2.96 - 2.77 (4H, m), 2.65 - 2.57 (2H, m), 2.20 - 2.07 (IH, m), 2.00 - 1.37 (3H, m) ppm. Anal.. Calc for C24H28F3N3O2 • 2HC1 • 2H2O: C; 51.80 %, H, 6J6 %, N, 7.55 % . Found: C; 51.45 %, H; 5.91 %, N, 7.38 % .
Example 12 Preparationof 2 '.3 )-3-f(6-Methoxy-l-methyl-2-thioxo-1.2.3.4-tetrahydroquinolin-7- yl)methyllamino-2-phenylpiperidine dihydrochloride (Compound 49) (i) 6-Methoxy-l-methyl-2-thioxo-1.2.3.4-tetrahydroquinoline (Compound 46)
To a stiπed solution of compound 15 (350 mg, 1.83 mmol) in toluene (5 ml) was added Lawesson's Reagent (407 mg, 1.01 mmol), and refluxed for 1.5 h. The solvent was evaporated, and the residue was purified by a column chromatography on silicagel to give compound 46 (363 mg, 1.75 mmol, 96%) as a white solid. 'H-NMR (270MHz) δ (CDC13) 7.06 (IH, d, 7 = 8.8 Hz), 6.79 (IH, dd, 7 =
8.8, 2.9 Hz), 6.72 (IH, d, 7 = 2.9 Hz), 3.89 (3H, s), 3.81 (3H, s), 3.21 - 3J4 (2H, m), 2.81 - 2.74 (2H, m) ppm.
(ii) 6-Methoxy-l-methyl-2-thioxo-1.2.3.4-tetrahydroquinoline-7-carboxaldehyde
(Compound 47) This compound was prepared from compound 46 in the same manner of compound 3.
'H-NMR (270MHz) δ (CDC13) 10.44 (IH, s), 7.60 (IH, s), 6.83 (IH, s), 3.96 (3H, s), 3.92 (3H, s), 3.24 - 3J6 (2H, m), 2.91 - 2.83 (2H, m) ppm. (iii) (25'.i )-l-tgrt-Butoxycarbonyl-3-r(6-methoxy-l-methyl-2-thioxo-l .2.3.4- tetrahydroquinolin-7-yl)methynamino-2-phenylpiperidine (Compound 48)
This compound was prepared from compound 47 and compound 9 in the same manner of compound 11.
'H-NMR (270MHz) δ (CDC13) 7.60 - 7.53 (2H, m), 7.36 - 7.23 (3H, m), 7.04 (IH, s), 6.60 (IH, s), 5.53 - 5.45 (IH, m), 3.99 - 3.89 (IH, m), 3.85 (3H, s), 3.82 (2H, s), 3.73 (3H, s), 3J9 - 3J2 (2H, m), 3.11 - 2.92 (2H, m), 2.78 - 2.70 (2H, m), 1.90 - 1.50 (4H, m), 1.40 (9H, s) ppm.
(iv) (25.3 )-3-r(6-Methoxy-l-methyl-2-thioxo-1.2.3.4-tetrahvdroquinolin-7- yl)methyl1amino-2-phenylpiperidine dihydrochloride (Compound 49)
This compound was prepared from compound 48 in the same manner of compound 12. mp 245 - 246 °C. IR » (KBr) 3445, 2930, 2680, 1561, 1477, 1434, 1259, 1105 cm '. 'H-NMR (270 MHz) δ (free base; CDC13) 7.33 - 7.21 (5H, m), 6.82 (IH, s), 6.50 (IH, s), 3.92 (IH, d, 7 = 2.2 Hz), 3.75 (3H, s), 3.66 (IH, d, 7 = 13.9 Hz), 3.55 (3H, s), 3.43 (IH, d, 7 = 13.9 Hz), 3.33 - 3.24 (IH, m), 3.17 - 3J0 (2H, m), 2.88 - 2.67 (4H, m), 2.20 - 2.11 (IH, m), 2.03 - 1.80 (IH, m), 1.75 - 1.55 (IH, m), 1.54 - 1.42 (IH, m) ppm. Anal.. Calc for C23H29N3OS - 2HCl - 0JH2O: C; 58.46 % , H, 6.88 % , N, 8.82 % . Found: C; 58.74 %, H; 6.69 %, N, 8.93 %.
Example 13 Preparation of (2 .i J-3-r(7-Methoxy-l-methyl-2-oxo-2.3.4.5-tetrahvdro-lH- benzazepin-8-yl)methyl"|amino-2-phenylpiperidine dihydrochloride (Compound 54) (i) 7-Methoxy-2-oxo-2.3.4.5-tetrahydro-lH-benzazepine (Compound 50) To a stiπed solution of 6-methoxy-l -tetralone (1.0 g, 5.7 mmol) in CH2C12 (10 ml) was added cone. H2SO4 (5 ml) at 0°C, and then NaN3(1.0 g) was added gradually over 30 min. The mixture was warmed up to room temperature, and stiπed for 3h. The mixture was cooled, basified with NaOH aq., and extracted with CH2C12. The organic layers were combined, dried (MgSO4), filtered, and concentrated, the residue was purified by a column chromatography on silicagel to give compound 50 (0J0 g, 0.52 mmol, 9.2%) as a white solid.
'H-NMR (270MHz) δ (CDC13) 7.65 (IH, br. s), 6.94 - 6.88 (IH, m), 6.78 - 6.68 (2H, m), 3.81 (3H, s), 2.77 (2H, t, 7 = 7.0 Hz), 2.37 - 2.15 (4H, m) ppm. (ii) 7-Methoxy-2-oxo-2.3.4.5-tetrahydro-lH-benzazepine-8-carboxaldehyde (Compound 51}
This compound was prepared from compound 50 in the same manner of compound 3.
This was employed in the next step without further purification. (iii) 7-Methoxy-l-methyl-2-oxo-2.3.4.5-tetrahydro-lH-benzazepine-8-carboxaldehyde (Compound 52)
This compound was prepared from compound 51 in the same manner of compound 30.
'H-NMR (270MHz) δ (CDC13) 10.43 (IH, s), 7.63 (IH, s), 6.85 (IH, s), 3.97 (3H, s), 3.33 (3H, s), 2.82 - 2.74 (2H, m), 2.38 - 2.13 (4H, m) ppm. (iv) (25, 5)-l-tgrr-Butoxycarbonyl-3-r(7-methoxy-l-methyl-2-oxo-2.3.4.5-tetrahvdro- lH-benzazepin-8-yl)methyllamino-2-phenylpiperidine (Compound 53)
This compound was prepared from compound 52 and compound 9 in the same manner of compound 11.
'H-NMR (270MHz) δ (CDC13) 7.62 - 7.55 (2H, m), 7.38 - 7.22 (3H, m), 7.01 (IH, s), 6.60 (IH, s), 5.53 - 5.45 (IH, m), 4.00 - 3.72 (3H, m), 3.72 (3H, s), 3.27 (3H, s), 3.12 - 2.92 (2H, m), 2.70 - 2.60 (2H, m), 2.30 - 2.05 (4H, m), 1.92 - 1.40 (4H, m), 1.40 (9H, s) ppm.
(v) (2 J-3-r(7-Methoxy-l-methyl-2-oxo-2.3.4.5-tetrahydro-lH-benzazepin-8- yl)methvnamino-2-phenylpiperidine dihydrochloride (Compound 54)
This compound was prepared from compound 53 in the same manner of compound 12. mp 236 - 238 °C. IR ι>max (KBr) 3445, 2935, 2740, 1656, 1508, 1435, 1248,
1166 cm"'. 'H-NMR (270 MHz) δ (free base; CDC13) 7.43 - 7.25 (5H, ), 6.82 (IH, s), 6.50 (IH, s), 4.12 - 4.08 (IH, m), 3.70 (IH, d, 7 = 13.9 Hz), 3.58 - 3.43 (2H, m), 3.52 (3H, s), 3.22 (3H, s), 3.00 - 2.86 (2H, m), 2.68 - 2.58 (2H, m), 2.30 - 2.00 (6H, ), 1.75 - 1.54 (2H, m) ppm. Anal. Calc for C24H3,N3O2-2HC1 -0.5H2O: C, 60.63 %, H, 7.21 %, N, 8.84 %. Found: C, 60.95 %, H, 7.11 % , N, 8.87 %.
Example 14 Preparation of (2 .55'J-3-[(7-Methoxy-l-methyl-2-oxo-l .2.3.4-tetrahydroquinolin-6- yl)methynamino-2-phenylpiperidine dihydrochloride (Compound 59) (i) 7-Methoxy-2-oxo-1.2.3.4-tetrahydroquinoline (Compound 55) This compound was prepared according to the procedure (Chem. Pharm. Bull. ,
9, 970 (1961)). (ii) 7-Methoxy-l-methyl-2-oxo-1.2.3.4-tetrahydroquinoline (Compound 56)
This compound was prepared from compound 55 in the same manner of compound 30. Η-NMR (270 MHz) δ (CDC13) 7.06 (IH, d, 7 = 8.8 Hz), 6.57 - 6.48 (2H, m), 3.81 (3H, s), 3.33 (3H, s), 2.86 - 2.78 (2H, m), 2.68 - 2.58 (2H, m) ppm. (iii) 7-Methoxy- 1 -methyl-2-oxo- 1.2.3.4-tetrahydroquinoline-6-carboxaldehyde (Compound 57)
This compound was prepared from compound 56 in the same manner of compound 3.
•H-NMR (270MHz) δ (CDC13) 10.35 (IH, s), 7.65 (IH, s), 6.52 (IH, s), 3.96 (3H, s), 3.41 (3H, s), 2.93 - 2.85 (2H, m), 2.70 - 2.62 (2H, m) ppm. (iv) (2S.35 l-tgrt-Butoxycarbonyl-3-I(7-methoxy-l-methyl-2-oxo-l .2.3.4- tetrahydroquinolin-6-yl)methynamino-2-phenylpiperidine (Compound 58)
This compound was prepared from compound 57 and compound 9 in the same manner of compound 11. 'H-NMR (270MHz) δ (CDC13) 7.62 - 7.55 (2H, m), 7.36 - 7.22 (3H, m), 6.97
(IH, s), 6.44 (IH, s), 5.53 - 5.46 (IH, m), 3.99 - 3.89 (IH, m), 3.85 - 3.69 (2H, m),
3.72 (3H, s), 3.35 (3H, s), 3.10 - 2.91 (2H, m), 2.84 - 2.76 (2H, ), 2.64 - 2.58
(2H, m), 1.88 - 1.52 (4H, m), 1.40 (9H, s) ppm.
(v) (25.i J-3-r(7-Methoxy-l-methyl-2-oxo-1.2.3.4Jetrahvdroquinolin-6- yl)methyl1amino-2-phenylpiperidine dihydrochloride (Compound 59)
This compound was prepared from compound 58 in the same manner of compound 12. mp 243 - 244 °C. IR *vax(KBr) 3450, 2940, 2785, 2700, 1679, 1578, 1427,
1260, 1169, 1154 cm'. 'H-NMR (270 MHz) δ (free base; CDC13) 7.38 - 7.23 (5H, m), 6.72 (IH, s), 6.32 (IH, s), 3.91 (IH, d, 7 = 2.2 Hz), 3.61 (IH, d,7 = 13.6Hz),
3.50 (3H, s), 3.39 (IH, d, 7 = 13.6 Hz), 3.35 - 3.27 (IH, m), 3.32 (3H, s), 2.88 -
2.57 (6H, m), 2.20 - 2.12 (IH, m), 2.02 - 1.85 (IH, m), 1.70 - 1.55 (IH, m), 1.49 - 1.38 (IH, m) ppm. Anal. Calc for C23H29N3O2 -2HCl: C, 61.06 %, H, 6.91 % , N,
9.29 %. Found: C, 60.67 %, H, 6.97 %, N, 9.57 %. Example 15
Preparation of (2S S)-3-r(7-Methoxy-l-methyl-2-oxo-4-trifluoromethyl-l .2.3.4- tetrahydroquinolin-6-yl)methynamino-2-phenylpiρeridine dihydrochloride (Compound
£5)
(i) 7-Methoxy-4-trifluoromethyl-2-quinolone (Compound 60) This compound was prepared according to the procedure (7. Org. Chem. , 45,
2285 (1980)).
(ii) 7-Methoxy-l-methyl-4-trifluoromethyl-2-quinolone (Compound 61)
This compound was prepared from compound 60 in the same manner of compound 30. 'H-NMR (270 MHz) δ (CDC13) 7.82 - 7.75 (IH, m), 6.95 - 6.83 (3H, m), 3.94
(3H, s), 3.72 (3H, s) ppm.
(iii) 7-Methoxy-l-methyl-2-oxo-4-trifluoromethyl-1.2.3.4-tetrahydroquinoline (Compound 62)
The solution of 61 (200 mg, 0.78 mmol) in methanol (6 ml) was hydrogenated over 10% Pd-C (0J g) at atomospheric pressure for 22 houres. The catalyst was filtered off, and washed with methanol. The filtrate was concentrated to give 62 (190 mg, 0.75 mmol, 96%) as a white solid.
'H-NMR (270 MHz) δ (CDC13) 7.19 (IH, d, 7 = 8.1 Hz), 6.65 - 6.58 (2H, m), 3.84 (3H, s), 3.60 - 3.42 (IH, m), 3.35 (3H, s), 3.07 - 2.83 (2H, m) ppm. (iv) 7-Methoxy-l-methyl-2-oxo-4-trifluoromethyl-1.2.3.4-tetrahydroquinoline-6- carboxaldehyde (Compound 63) This compound was prepared from compound 62 in the same manner of compound 3.
'H-NMR (270MHz) δ (CDC13) 10.35 (IH, s), 7.77 (IH, s), 6.58 (IH, s), 4.00 (3H, s), 3.65 - 3.51 (IH, m), 3.43 (3H, s), 3.07 (IH, dd, 7 = 16.9, 2.2 Hz), 2.91 (IH, dd, 7 = 16.9, 7.3 Hz) ppm. (v) (2S.3S)- 1 -tgrt-Butoxycarbonyl-3-[(7-methoxy- 1 -methyl-2-oxo-4-trifluoromethyl- 1.2.3.4-tetrahydroquinolin-6-yl)methyllamino-2-phenylpiperidine (Compound 64)
This compound was prepared from compound 63 and compound 9 in the same manner of compound 11.
'H-NMR (270MHZ) δ (CDC13) 7.61 - 7.52 (2H, m), 7.36 - 7.22 (3H, m), 7.12 and 7.52 (total IH, each s), 6.46 (IH, s), 5.52 - 5.42 (IH, m), 4.00 - 3.89 (IH, m), 3.88 - 3.71 (2H, m), 3.75 (3H, s), 3.52 - 3.37 (IH, m), 3.36 (3H, s), 3.09 - 2.76 (4H, m), 1.90 - 1.45 (4H, m), 1.40 (9H, s) ppm.
(vi) (2 .i J-3-r(7-Methoxy-l-methyl-2-oxo-1.2.3.4Jetrahvdroquinolin-6- yl)methyl1amino-2-phenylpiperidine dihydrochloride (Compound 65) This compound was prepared from compound 64 in the same manner of compound 12. mp 255 - 256 °C. IR ^ (KBr) 3430, 2935, 2660, 1680, 1626, 1416, 1371 , 1340, 1124, 1113 cm '. 'H-NMR (270 MHz) δ (free base; CDC13) 7.37 - 7.22 (5H, m), 6.81 and 6.78 (total IH, each s), 6.36 and 6.31 (total IH, each s), 3.93 - 3.88 (IH, m), 3.70 - 3.53 (4H, m), 3.46 - 3.24 (6H, m), 3.02 - 2.75 (4H, ), 2.17 - 2.05 (IH, m), 2.03 - 1.38 (3H, m) ppm. Anal.. Calc for C24H2gF3N3O2 -2HCl: C, 55.39 %, H, 5.81 %, N, 8.07 %. Found: C, 55.03 %, H, 5.99 %, N, 7.91 %. Example 16
Preparation of (2S.JSJ-3J(6-Methoxy-l-methyl-2-oxo-4H-3.1-benzoxazin-7- yl)methyl1amino-2-phenylpiperidine dihydrochloride (Compound 70) (i) 6-Methoxy-4H-3J-benzoxazin-2-one (Compound 66) This compound was prepared according to the procedure (7. Med. Chem. , 30,
295 (1987)). (ii) 6-Methoxy-l-methyl-4H-3J-benzoxazin-2-one (Compound 67)
This compound was prepared from compound 66 in the same manner of compound 30. 'H-NMR (270 MHz) δ (CDC13) 6.90 - 6.83 (2H, m), 6.71 - 6.67 (IH, m), 5.16
(2H, s), 3.80 (3H, s), 3.35 (3H, s) ppm.
(iii)6-Methoxy-l-methyl-2-oxo-4H-3J-benzoxazine-7-carboxaldehyde(Compound68) This compound was prepared from compound 67 in the same manner of compound 3. 'H-NMR (270MHz) δ (CDC13) 10.46 (IH, s), 7.39 (IH, s), 6.81 (IH, s), 5.22
(2H, s), 3.94 (3H, s), 3.40 (3H, s) ppm.
(iv)(25' 5^-l-tgrt-Butoxycarbonyl-3-[(6-methoxy-l-methyl-2-oxo-4H-3J-benzoxazin- 7-yl)methyl1amino-2-phenylpiperidine (Compound 69)
This compound was prepared from compound 68 and compound 9 in the same manner of compound 11.
•H-NMR (270MHz) δ (CDC13) 7.61 - 7.52 (2H, m), 7.35 - 7.22 (3H, m), 6.85
(IH, s), 6.57 (IH, s), 5.55 - 5.43 (IH, m), 5.14 (2H, s), 4.00 - 3.92 (IH, m), 3.91 -
3.87 (2H, m), 3.70 (3H, s), 3.32 (3H, s), 3.09 - 2.92 (2H, m), 1.92 - 1.50 (4H, m),
1.40 (9H, s) ppm. (v) (2 .i5J-3-r(6-Methoxy-l-methyl-2-oxo-4H-3J-benzoxazin-7-yl)methynamino-2- phenylpiperidine dihydrochloride (Compound 70)
This compound was prepared from compound 69 in the same manner of compound 12. mp 235 - 237 °C. IR » (KBr) 3420, 2935, 2665, 1728, 1564, 1508, 1481, 1429, 1302, 1037 cm"1. Η-NMR (270 MHz) δ (free base; CDC13) 7.35 - 7.20 (5H, m), 6.61 (IH, s), 6.47 (IH, s), 5.11 (2H, s), 3.90 - 3.87 (IH, m), 3.65 (IH, d, 7 =
14.3 Hz), 3.53 (3H, s), 3.44 (IH, d, 7 = 14.3 Hz), 3.30 - 3.18 (IH, m), 3.21 (3H, s), 2.86 - 2.74 (2H, m), 2.18 - 2.07 (IH, m), 1.98 - 1.38 (3H, m) ppm. Anal.. Calc for C22H27N3O3 - 2HCl: C, 58.15 %, H, 6.43 %, N, 9.25 % . Found: C, 57.83 % , H, 6.36 96, N, 9.18 % .
Example 17 Preparation of (2S J-3-r(6-Methoxy-l-methyl-2-oxo-4H-3J-benzothiazin-7- yl)methyllamino-2-phenylpiperidine dihydrochloride (Compound 75) (i) 6-Methoxy-4H-3J-benzothiazin-2-one (Compound 71)
This compound was prepared according to the procedure (7. Med. Chem. , 30, 295 (1987)). (ii) 6-Methoxy-l-methyl-4H-3J-benzothiazin-2-one (Compound 72)
This compound was prepared from compound 71 in the same manner of compound 30.
'H-NMR (270 MHz) δ (CDC13) 6.98 (IH, d, 7 = 8.8 Hz), 6.84 (IH, dd, 7 = 8.8, 2.9 Hz), 6.75 (IH, d, 7 = 2.9 Hz), 3.93 (2H, s), 3.81 (3H, s), 3.42 (3H, s) ppm.
(iii) 6-Methoxy-l-methyl-2-oxo-4H-3J-benzothiazine-7-carboxaldehyde (Compound 73}
This compound was prepared from compound 72 in the same manner of compound 3. 'H-NMR (270MHz) δ (CDC13) 10.45 (IH, s), 7.52 (IH, s), 6.86 (IH, s), 3.99
(2H, s), 3.96 (3H, s), 3.43 (3H, s) ppm.
(iv) (2S.3S)- 1 -tgrt-Butoxycarbonyl-3-r(6-methoxy- 1 -methyl-2-oxo-4H-3.1 -benzothiazin- 7-yl)methyllamino-2-phenylpiperidine (Compound 74)
This compound was prepared from compound 73 and compound 9 in the same manner of compound 11.
'H-NMR (270MHz) δ (CDC13) 7.62 - 7.54 (2H, m), 7.37 - 7.22 (3H, m), 6.96 (IH, s), 6.62 (IH, s), 5.54 - 5.42 (IH, m), 4.02 - 3.90 (IH, m), 3.91 (2H, s), 3.82 (2H, s), 3.72 (3H, s), 3.38 (3H, s), 3.10 - 2.93 (2H, m), 1.93 - 1.50 (4H, m), 1.40 (9H, s) ppm. (v) (2S.i J-3-r(6-Methoxy-l-methyl-2-oxo-4H-3J-benzothiazin-7-yl)methvnamino-2- phenylpiperidine dihydrochloride (Compound 75)
This compound was prepared from compound 74 in the same manner of compound 12. mp 252 - 254 °C. IR ^max (KBr) 3450, 2935, 2655, 1647, 1562, 1514, 1470, 1450, 1434, 1416, 1269, 1166, 1038 cm '. 'H-NMR (270 MHz) δ (free base; CDC13) 7.36 - 7J9 (5H, m), 6.72 (IH, s), 6.52 (IH, s), 3.93 - 3.87 (3H, m), 3.64 (IH, d, 7 = 14.3 Hz), 3.54 (3H, s), 3.43 (IH, d, 7 = 14.3 Hz), 3.31 - 3.22 (IH, m), 3.28 (3H, s), 2.87 - 2.74 (2H, m), 2J8 - 2.07 (IH, m), 2.00 - 1.40 (3H, m) ppm. Anal.. Calc for C22H27N3O2S - 2HCl: C, 56.17 %, H, 6.21 %, N, 8.93 % . Found: C, 55.81 %, H, 6.37 %, N, 8.67 % .
Example 18 Preparationof(2 5^-3-((7-Methoxy-4-methyl-3-oxo-3.4-dihydro-1.4-benzothiadin-6- yl)methyl)amino-2-phenylpiperidine dihydrochloride (Compound 79) (i) 7-Methoxy-4-methyl-3-oxo-3.4-dihydro-1.4-benzothiadine (Compound 76)
This compound was prepared according to the procedure (Indian 7. Chem. Seer B, 29B, 297(1990)). {ii} 7-Methoxy-4-methyl-3-oxo-3.4-dihydro-1.4-benzothiadine-6-carboxaldehyde
(Compound 77)
This compound was prepared from compound 76 in the same manner of compound 3.
'H-NMR (270 MHz) δ (CDC13) 10.40 (IH, s), 7.53 (IH, s), 6.99 (IH, s), 3.93 (3H, s), 3.46 (2H, s), 3.45 (3H, s) ppm.
(iii) r25'.i )-l-tgrt-Butoxycarbonyl-3-((7-methoxy-4-methyl-3-oxo-3.4-dihydro-1.4- benzothiadin-6-yl)methyl)amino-2-phenylpiperidine (Compound 78)
This compound was prepared from compound 77 and compound 9 in the same manner of compound 11. 'H-NMR (270 MHz) δ (CDC13) 7.63 - 6.75 (7H, m), 5.48 (IH, br), 4.06 - 2.94
(14H, m), 1.95 - 1.20 (4H, m), 1.40 (9H, s) ppm. This was employed in the next step without further purification. (iv) (25 5')-3-((7-Methoxy-4-methyl-3-oxo-3.4-dihvdro-1.4-benzothiadin-6- yl)methyl)amino-2-phenylpiperidine dihydrochloride (Compound 79) This compound was prepared from compound 78 in the same manner of compound 12. mp 263 - 269 °C. 'H-NMR (270 MHz) δ (free base; CDC13) 7.39 - 6.99 (7H, m), 3.92- 2.75 (6H, m), 3.52 (3H, s), 3.36 (2H, s), 3.28 (3H, s), 2.20 - 1.40 (4H, m) ppm.
Example 19 Preparation of (25' )-3-((7-Methoxy-4-methyl-3-oxo-3.4-dihydro-l .4-benzoxadin-6- yl)methyl)amino-2-phenylpiperidine dihydrochloride (Compound 83)
(i) 7-Methoxy-4-methyl-3-oxo-3.4-dihydro-1.4-benzoxadine (Compound 80)
This compound was prepared according to the procedure (US 4552956).
(ii) 7-Methoxy-4-methyl-3-oxo-3.4-dihydro-1.4-benzoxadine-6-carboxaldehyde
(Compound 81) This compound was prepared from compound 80 in the same manner of compound 3.
'H-NMR (270 MHz) δ (CDC13) 10.35 (IH, s), 7.45 (IH, s), 6.62 (IH, s), 4.70 (2H, s), 3.91 (3H, s), 3.38 (3H, s) ppm.
(iii) (25 5^-l-tgrt-Butoxycarbonyl-3-((7-methoxy-4-methyl-3-oxo-3.4-dihydro-1.4- benzoxadin-6-yl)methyl)amino-2-phenylpiperidine (Compound 82)
This compound was prepared from compound 81 and compound 9 in the same manner of compound 11.
'H-NMR (270 MHz) δ (CDC13) 7.63 - 6.49 (7H, m), 5.50 (IH, br), 4.56 (2H, s), 4.00 - 2.90 (6H, m), 3.67 (3H, s), 3.30 (3H, s), 1.90 - 1.30 (4H, m), 1.40 (9H, s) ppm.
This was employed in the next step without further purification.
(iv) (25.i5)-3-((7-Methoxy-4-methyl-3-oxo-3.4-dihydro-1.4-benzoxadin-6- yl)methyl)amino-2-phenylpiperidine dihydrochloride (Compound 83)
This compound was prepared from compound 82 in the same manner of compound 12. mp 263 - 267 °C. 'H-NMR (270 MHz) δ (free base; CDC13) 7.36 - 6.39 (7H, m), 4.55 (2H, s), 3.92 - 2.72 (6H, m), 3.49 (3H, s), 3.21 (3H, s), 2.20 - 1.37 (4H, m) ppm.
Example 20 Preparation of (2S.3S)-3-r(6-Methoxy-1.3.3-trimethyl-2Jhioxo-2.3-dihydroindol-5-yl) methyπamino-2-phenylpiperidine dihydrochloride (Compound 87) (i) 6-Methoxy-1.3.3-trimethyl-2-thioxo-2.3-dihvdroindol (Compound 84) This compound was prepared from compound 2 in the same manner of compound 46.
'H-NMR (270MHz) δ (CDC13) 7.19 (IH, d, 7 = 8.4 Hz), 6.72 - 6.55 (2H, m), 3.85 (3H, s), 3.63 (3H, s), 1.41 (6H, s) ppm. £11} 6-Methoxy-1.3.3-trimethyl-2-thioxo-2.3-dihydroindol-5-carboxaldehyde
(Compound 85)
This compound was prepared from compound 84 in the same manner of compound 3.
'H-NMR (270MHz) δ (CDC13) 10.42 (IH, s), 7.76 (IH, s), 6.60 (IH, s), 4.01 (3H, s), 3.68 (3H, s), 1.42 (6H, s) ppm.
(iii) (2S )-l-tgrt-Butoxycarbonyl-3-[(6-methoxy-1.3.3-trimethyl-2-thioxo-2.3- dihydroindol-5-yl)methyllamino-2-phenylpiperidine (Compound 86)
This compound was prepared from compound 85 and compound 9 in the same manner of compound 11. 'H-NMR (270MHz) δ (CDC13) 7.64 - 7.56 (2H, m), 7.37 - 7.22 (3H, m), 7.11
(IH, s), 6.51 (IH, s), 5.57 - 5.44 (IH, m), 3.98 - 3.70 (3H, m), 3.76 (3H, s), 3.64 (3H, s), 3.13 - 2.92 (2H, m), 1.90 - 1.40 (4H, m), 1.41 (9H, s), 1.38 (3H, s), 1.37 (3H, s) ppm.
(iv) (2 .i5)-3-r(6-Methoxy-1.3.3-trimethyl-2-thioxo-2.3-dihvdroindol-5- yl)methyl1amino-2-phenylpiperidine dihydrochloride (Compound 87)
This compound was prepared from compound 86 in the same manner of compound 12. mp 234 - 236 °C. IR vw (KBr) 3435, 2970, 2934, 2685, 1627, 1559, 1447, 1430, 1370, 1278, 1056 cm '. 'H-NMR (270 MHz) δ (free base; CDC13) 7.37 - 7.23 (5H, m), 6.89 (IH, s), 6.40 (IH, s), 3.91 (IH, d, 7 = 2.2 Hz), 3.67 (IH, d, 7 = 13.9 Hz), 3.62 (3H, s), 3.57 (3H, s), 3.42 (IH, d, 7 = 13.9 Hz), 3.33 - 3.22 (IH, m), 2.88 - 2.73 (2H, m), 2.19 - 1.35 (4H, m), 1.35 (3H, s), 1.34 (3H, s) ppm. Anal. Calc for C24H31N3OS - 2HCl: C; 59.74 %, H, 6.89 %, N, 8.71 %. Found: C; 60.02 % , H; 6.91 %, N, 8.64 %. Example 21
Preparation of (2S .3S)-3-I(7-Methoxy- 1 -methyl-2-thioxo- 1.2.3.4-tetrah vdroquinol i n-6- yl) methynamino-2-phenylpiperidine dihydrochloride (Compound 91) (i) 7-Methoxy-l-methyl-2-thioxo-1.2.3.4-tetrahydroquinolin (Compound 88)
This compound was prepared from compound 55 in the same manner of compound 46.
'H-NMR (270MHz) δ (CDC13) 7.08 (IH, d, 7 = 8.1 Hz), 6.71 (IH, d, 7 = 2.6 Hz), 6.64 (IH, dd, 7 = 8.1, 2.6 Hz), 3.89 (3H, s), 3.83 (3H, s), 3.23 - 3.14 (2H, m), 2.78 - 2.68 (2H, m) ppm.
(ii) 7-Methoxy-l-methyl-2-thioxo-1.2.3.4-tetrahydroquinolin-6-carboxaldehyde
(Compound 89)
This compound was prepared from compound 88 in the same manner of compound 3.
'H-NMR (270MHz) δ (CDC13) 10.37 (IH, s), 7.65 (IH, s), 6.69 (IH, s), 3.98 (3H, s), 3.95 (3H, s), 3.24 - 3.16 (2H, m), 2.82 - 2.74 (2H, m) ppm.
(iii) (2S )-l-tgrt-Butoxycarbonyl-3-r(7-methoxy-l-methyl-2-thioxo-l .2.3.4- tetrahydroquinolin-6-yl)methyl1amino-2-phenylpiρeridine (Compound 90) This compound was prepared from compound 89 and compound 9 in the same manner of compound 11.
'H-NMR (270MHz) δ (CDC13) 7.60 - 7.53 (2H, m), 7.37 - 7.23 (3H, m), 6.99 (IH, s), 6.56 (IH, s), 5.53 - 5.43 (IH, m), 3.99 - 3.88 (IH, m), 3.90 (3H, s), 3.85 - 3.65 (2H, m), 3.73 (3H, s), 3.18 - 3.11 (2H, m), 3.10 - 2.90 (2H, m), 2.72 - 2.63 (2H, m), 1.90 - 1.50 (4H, m), 1.41 (9H, s) ppm.
(iv) (2 5)-3-r(7-Methoxy-l-methyl-2-thioxo-1.2.3.4-tetrahydroquinolin-6-yl) methyllamino-2-phenylpiperidine dihydrochloride (Compound 91)
This compound was prepared from compound 90 in the same manner of compound 12. mp.219 - 221 °C. IR ι (KBr) 3435, 2940, 2660, 1626, 1558, 1464, 1430,
1416, 1369, 1338, 1103 cm'. 'H-NMR (270 MHz) δ (free base; CDC13) 7.42 - 7.23
(5H, m), 6.80 (IH, s), 6.45 (IH, s), 4.05 - 4.01 (IH, m), 3.87 (3H ,s), 3.66 (IH, d,
7 = 13.9 Hz), 3.52 (3H, s), 3.50 - 3.40 (IH, m), 3.43 (IH, d, 7 = 13.9 Hz), 3.18 -
3J0 (2H, m), 2.97-2.83 (2H, m), 2.68 - 2.58 (2H, m), 2.20-2.00(2H, m), 1.80- 1.50 (2H, m) ppm. Anal.. Calc for C23H29N3OS • 2HC1 • 0.5H2O: C; 57.85 % , H, 6.75
%, N, 8.80 %. Found: C; 57.81 %, H; 6.52 %, N, 8.68 %. Example 22 Preparation of (2S.3S) -3- ((1.6-Dimethoxy-2-oxo-1.2.3.4-tetrahydroquinolin -7- yl)methyl)amino-2-phenylpiperidine dihydrochloride (Compound 95) (i) 1.6-Dimethoxy-2-oxo-1.2.3.4-tetrahydroquinoline (Compound 92) This compound was prepared according to the procedure (Tetrahedron, 43,
2577(1987)).
(ii) 1.6-Dimethoxy-2-oxo-l .2.3.4-tetrahydroquinoline-7-carboxaldehyde (Compound 93}
This compound was prepared from compound 92 in the same manner of compound 3.
(iii) 2S.3S)- l -tgrt-Butoxycarbonyl-3-((1.6-dimethoxy-2-oxo- 1 .2.3.4- tetrahydroquinolin-7-yl)methyl)amino-2-phenylpiperidine (Compound 94)
This compound was prepared from compound 93 and compound 9 in the same manner of compound 11. This was employed in the next step without further purification.
(vV2 .i5^-3-((1.6-Dimethoxy-2-oxo-1.2.3.4-tetrahvdroquinolin-7-yl)methyl)amino-2- phenylpiperidine dihydrochloride (Compound 95)
This compound was prepared from compound 94 in the same manner of compound 12. Example 23
Preparation of (2 .3 )-3-r(l-Difluoromethyl-6-methoxy-2-oxo-l .2.3.4- tetrahydroquinolin-7-yl)methynamino-2-phenylpiperidine dihydrochloride (Compound 99)
(i) 6-Methoxy-2-oxo-1.2.3.4-tetrahydroquinoline-7-carboxaldehyde (Compound 96) This compound was prepared from compound 29 in the same manner of compound 3
'H-NMR (270 MHz) δ (CDC13) 10.40 (s, IH), 7.80 (br, IH), 7.22 (s, IH), 6.84 (s, IH), 3.92 (s, 3H), 3.03 (t, 2H, 7 = 7Hz), 2.64 (t, 2H, 7 = 7Hz). (ii) l-Difluoromethyl-6-methoxy-2-oxo-1.2.3.4-tetrahydroquinoline-7- carboxaldehyde (Compound 97)
This compound was prepared from compound 96 and CF2HC1 in the same manner of compound 30.
'H-NMR (270 MHz) δ (CDC13) 10.42 (s, IH), 7.92 (s, IH), 7.70 (t, IH, 7 = 59.7Hz), 6.86 (s, IH), 3.94 (s, 3H), 3.04 - 2.95 (m, 2H), 2.75 - 2.67 (m, 2H). (iii) (25' 5^-l-tgrt-Butoxycarbonyl-3-r(l-difluoromethyl-6-methoxy-2-oxo-l .2.3.4- tetrahydroquinolin-7-yl)methyl]amino-2-phenylpiperidine (Compound 98)
This compound was prepared from compound 97 and compound 9 in the same manner of compound 11.
'H-NMR (270 MHz) δ (CDC13) 7.71 (t, IH, 7 = 60JHz), 7.62 - 7.52 (m, 2H), 7.43 (s, IH), 7.35 - 7.20 (m, 3H), 6.63 (s, IH), 5.45 - 5.32 (m, IH), 4.02 - 3.92 (m, IH), 3.81 (s, 2H), 3.71 (s, 3H), 3.12 - 2.95 (m, 2H), 2.93 - 2.84 (m, 2H), 2.69 - 2.61 ( , 2H), 1.93 - 1.50 (m, 4H), 1.39 (s, 9H). (iv) (2 )-3-r(l-Difluoromethyl-6-methoxy-2-oxo-1.2.3.4-tetrahvdroquinolin-7- yl)methyl]amino-2-phenylpiperidine dihydrochloride (Compound 99)
This compound was prepared from compound 98 in the same manner of compound 12.
'H-NMR (270 MHz) δ (CDC13) 7.69 (t, IH, 7 = 60JHz), 7.42 - 7.15 (m, 6H), 6.50 (s, IH), 3.92 (d, IH, 7 = 1.8 Hz), 3.67 - 3.26 (m, 3H), 3.46 (s, 3H), 2.97 - 2.50 (m, 6H), 2.20 - 1.35 (m, 4H).
The chemical structures of the compounds prepared in Examples 1 to 23 are summarized in the follwing table.
TABLE
T
Figure imgf000045_0001
Ki) I(ii)
Ex.# fromula T Y X -N(R')C(=Q)W(R )(R3)-
1 I(ii) q* NH OCH3 -N(CH3)C(=O)C(CH3)2-
2 I(ii) p* NH OCH3 -N(CH3)C(=O)C(CH3)2-
3 Ki) q NH OCH, -N(CH3)C(=O)CH2CH2-
4 I(i) q NH OCH3 -N(CH3)C(=O)CHCH-
5 Ki) p NH OCH, -N(CH3)C(=O)CH2CH2-
6 Ki) P NH OCH(CH3)2 -N(CH3)C(=O)CH2CH2-
7 Ki) P NH OCH3 -N(CH3)C(=O)CHCH-
8 Ki) P NH OCH, -N(CH(CH3)2)C( = O)CH2CH2-
9 Ki) P NH OCH2F3 -N(CH3)C(=O)CH2CH2-
10 Ki) P NH OCHF2 -N(CH2CF3)C( = O)CH2CH2-
11 Ki) P NH OCH2CF3 -N(CH3)C( = O)CH2CH2-
12 Ki) P NH OCH3 -N(CH3)C(=S)CH2CH2-
13 Ki) P NH OCH3 -N(CH3)C( = O)CH2CH2CH2-
14 I(ii) P NH OCH3 -N(CH3)C(=O)CH2CH2-
15 I(ii) P NH OCH3 -N(CH3)C( = O)CH2CH(CF3)-
16 Ki) P NH OCH3 -N(CH3)C(=O)OCH2-
17 Ki) P NH OCH3 -N(CH3)C(=O)SCH2-
18 I(i) P NH OCH3 -N(CH3)C(=O)CH2S-
19 Ki) P NH OCH3 -N(CH3)C(=O)CH2O-
20 I(ii) P NH OCH3 -N(CH3)C(=S)C(CH3)2-
21 I(ii) P NH OCH, -N(CH3)C(=S)CH2CH2-
22 I(i) P NH OCH3 -N(OCH3)C(=O)CH2CH2-
23 Ki) P NH OCH3 -N(CF2H)C( = O)CH2CH2-
*q: (2S,3S)-2-diphenylethylquinuclidin-3-yl, p: (2S,3S)-2-phenylpiperidin-3-yl

Claims

1. A compound of the general formula
Figure imgf000046_0001
T 0) and its pharmaceutically acceptable salts, wherein W is methylene, ethylene, propylene, vinylene, -CH2-O-, -O-CH,-, -CH2-S- or -
S-CH2-;
R1, R2 and R3 are independently hydrogen, CrC3 alkyl, Cj-C3 alkoxy or halo Cr C3 alkyl, provided that when W is methylene, both R2 and R3 are not hydrogen;
X is halo, C,-C3 alkoxy, CrC3 alkyl, halo CrC3 alkoxy or C,-C3 alkenyl; Y is imino or oxy;
Q is oxygen or sulfur; and
T is (2S, J5)-2-diphenylmethylquinuclidin-3-yl, (25,5^)-2-phenylpiperidin-3-yl or (2S,5S)-2-diphenylmethyl-l-azanorbornan-3-yl.
2. A compound according to claim 1, wherein X is C,-C3 alkoxy or halo C,-C3 alkoxy; Y is imino; and T is (2 J5)-2-diphenylmethylquinuclidin-3-yl or (2S,3S)-2- phenylpiperidin-3-yl .
3. A compound according to claim 2, wherein R1 is methyl, isopropyl, methoxy or 2,2,2-trifluoroethyl; R2 and R3 are independently hydrogen, methyl or trifluoromethyl; and X is methoxy, isopropoxy, difluoromethoxy or trifuluoromethylmethoxy.
4. A compound according to claim 3 selected from
(25',55)-3-(6-methoxy-l,3,3-trimethyloxindol-5-yl)methylamino-2-phenylpiperidine or its salts;
(2£,JS)-3-(6-methoxy-l-methyl-2-oxo-l ,2,3,4-tetrahydroquinolin-7- yl)methylamino-2-phenylpiperidine or its salts;
(2S,55)-3-(6-isopropoxy-l-methyl-2-oxo-l ,2,3,4-tetrahydroquinolin-7- yl)methylamino-2-phenylpiperidine or its salts;
(25,55)-3-(l-isopropyl-6-methoxy-2-oxo-l ,2,3,4-tetrahydroquinolin-7- yl)methylamino-2-phenylpiperidine or its salts;
(25, 5S)-3-[(6-methoxy- 1 -methyl-2-thioxo- 1 , 2 , 3 , 4-tetrahydroquinolin-7- yl)methyl]amino-2-phenylpiperidine dihydrochloride or its salts; r21S',5S -3-[(7-methoxy-l-methyl-2-oxo- 1 ,2,3 , 4-tetrahydroquinolin-6- yl)methyl]amino-2-phenylpiperidine dihydrochloride or its salts; and (25,J-S,;-3-[(6-methoxy-l-methyl-2-oxo-4H-3,l-benzothiazin-7-yl)methyl]amino-2- phenylpiperidine dihydrochloride or its salts.
5. A compound according to claim 3 selected from (2iS,,^5)-2-diphenylmethyl-3-(6-methoxy-l,3,3-trimethyloxindol-5-yl)methylamino- l-azabicyclo[2.2.2]octane or its salts; (2S, JS)-2-diphenylmethyl-3-(6-methoxy- l -methyl-2-oxo- l ,2 ,3 ,4- tetrahydroquinolin-7-yl)methylamino-l-azabicyclo[2.2.2]octane or its salts;
(2S, 5£)-2-diphenylmethyl-3-(6-methoxy- 1 -methyl-2-oxo- 1 , 2-dihydroquinolin-7- yl)methylamino-l-azabicyclo[2.2.2]octane or its salts;
(2S, 3S)-3-[(6-methoxy- 1 -methyl-2-thioxo- 1 , 2 , 3 , 4-tetrahydroquinolin-7- yl)methyl]amino-2-phenylpiperidine dihydrochloride or its salts; and f25,55' 3-[(6-methoxy-l-methyl-2-oxo-4H-3,l-benzothiazin-7-yl)methyl]amino-2- phenylpiperidine dihydrochloride or its salts.
6. (2S,J5)-3-Amino-l-(tgrt-butoxycarbonyl)-2-phenylpiperidine.
7. A pharmaceutical composition for treating or preventing a gastrointestinal disorder, a central nervous system disorder, an inflammatory disease, emesis, urinary incontinence, pain, migraine or angiogensis in a mammalian subject which comprises a therapeutically effective amount of a compound of claim 1 together with a pharmaceutically acceptable carrier.
PCT/IB1996/000434 1995-07-07 1996-05-09 Substituted benzolactam compounds as substance p antagonists WO1997003066A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US08/983,004 US6180647B1 (en) 1995-07-07 1996-05-09 Substituted benzolactam compounds as substance P antagonists
DK96911079T DK0840732T3 (en) 1995-07-07 1996-05-09 Substituted benzolactam compounds as substance P antagonists
DE69612003T DE69612003T2 (en) 1995-07-07 1996-05-09 SUBSTITUTED BENZOLACTATE COMPOUNDS AS SUBSTANCE P-ANTAGONISTS
AT96911079T ATE199552T1 (en) 1995-07-07 1996-05-09 SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS
JP9505628A JP3042894B2 (en) 1995-07-07 1996-05-09 Substituted benzolactam compounds as substance P antagonists
EP96911079A EP0840732B1 (en) 1995-07-07 1996-05-09 Substituted benzolactam compounds as substance p antagonists
CA002226292A CA2226292C (en) 1995-07-07 1996-05-09 Substituted benzolactam compounds as substance p antagonists
MX9800187A MX9800187A (en) 1995-07-07 1996-05-09 Substituted benzolactam compounds as substance p antagonists.
US09/605,471 US6288225B1 (en) 1996-05-09 2000-06-28 Substituted benzolactam compounds as substance P antagonists
GR20010400624T GR3035774T3 (en) 1995-07-07 2001-04-20 Substituted benzolactam compounds as substance p antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JPPCT/JP95/01359 1995-07-07
JP9501359 1995-07-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08/983,004 A-371-Of-International US6180647B1 (en) 1995-07-07 1996-05-09 Substituted benzolactam compounds as substance P antagonists
US09/605,471 Division US6288225B1 (en) 1995-07-07 2000-06-28 Substituted benzolactam compounds as substance P antagonists

Publications (1)

Publication Number Publication Date
WO1997003066A1 true WO1997003066A1 (en) 1997-01-30

Family

ID=14126073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1996/000434 WO1997003066A1 (en) 1995-07-07 1996-05-09 Substituted benzolactam compounds as substance p antagonists

Country Status (11)

Country Link
US (1) US6180647B1 (en)
EP (1) EP0840732B1 (en)
JP (1) JP3042894B2 (en)
AT (1) ATE199552T1 (en)
CA (1) CA2226292C (en)
DE (1) DE69612003T2 (en)
DK (1) DK0840732T3 (en)
ES (1) ES2155601T3 (en)
GR (1) GR3035774T3 (en)
MX (1) MX9800187A (en)
WO (1) WO1997003066A1 (en)

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0824100A1 (en) * 1996-08-14 1998-02-18 Pfizer Inc. Piperidinylamino tricyclic compouds as substance P antagonists
WO1999025714A1 (en) * 1997-11-19 1999-05-27 Pfizer Pharmaceuticals Inc. Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists
US6133264A (en) * 1997-08-19 2000-10-17 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives for inhibiting skin erythema and/or skin pigmentation
WO2000068224A1 (en) * 1999-05-06 2000-11-16 Pfizer Products Inc. Substituted benzolactam compounds
WO2000071538A3 (en) * 1999-05-21 2001-02-22 Pfizer Prod Inc 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
US6316632B1 (en) 1999-05-17 2001-11-13 Pfizer Inc Process for preparing 2-phenyl-3-aminopyridine, substituted phenyl derivatives, thereof, and salts thereof
WO2001077100A3 (en) * 2000-04-10 2002-03-07 Pfizer Prod Inc Benzoamide piperidine compounds as substance p antagonists
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
EP1186318A3 (en) * 2000-09-06 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist
EP1095655A3 (en) * 1999-10-25 2003-03-26 Pfizer Products Inc. NK-1 receptor antagonists and eletriptan for the treatment of migraine
US6727249B2 (en) 2001-04-10 2004-04-27 Merck Sharp & Dohme Ltd. Azabicyclic ether derivatives and their use as therapeutic agents
US7084152B2 (en) 2000-07-11 2006-08-01 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
US7119207B2 (en) 2000-04-10 2006-10-10 Pfizer Inc Benzoamide piperidine containing compounds and related compounds
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
WO2007011820A2 (en) 2005-07-15 2007-01-25 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007093827A1 (en) 2006-02-15 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors
US7265116B2 (en) 1999-11-03 2007-09-04 Arm Technology, Inc. Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof
CZ299029B6 (en) * 1999-10-18 2008-04-09 Pfizer Products Inc. Mixture of piperidinylaminomethyl trifluoromethyl cyclic ether compounds, and processes as well as intermediates for its preparation
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US7514466B2 (en) 2004-04-27 2009-04-07 Wyeth Purification of progesterone receptor modulators
US7541357B2 (en) 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
WO2010132442A1 (en) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
EP2319838A1 (en) * 2002-06-07 2011-05-11 Cortical Pty Ltd Therapeutic Molecules and Methods-1
EP2336120A1 (en) 2007-01-10 2011-06-22 Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014085216A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
EP3327125A1 (en) 2010-10-29 2018-05-30 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11096950B2 (en) 2006-11-01 2021-08-24 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP4079856A1 (en) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058695A1 (en) * 2000-12-20 2002-08-01 Merck & Co., Inc. (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
US20040111410A1 (en) * 2002-10-14 2004-06-10 Burgoon David Alford Information reservoir
US20090197878A1 (en) * 2008-02-01 2009-08-06 Wyeth SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005729A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine therapeutic agents
EP0532456A1 (en) * 1991-08-12 1993-03-17 Ciba-Geigy Ag 1-Acylpiperidine derivatives and their use as substance P antagonists
WO1994013663A1 (en) * 1992-12-10 1994-06-23 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680283A (en) 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005729A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine therapeutic agents
EP0532456A1 (en) * 1991-08-12 1993-03-17 Ciba-Geigy Ag 1-Acylpiperidine derivatives and their use as substance P antagonists
WO1994013663A1 (en) * 1992-12-10 1994-06-23 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists

Cited By (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0824100A1 (en) * 1996-08-14 1998-02-18 Pfizer Inc. Piperidinylamino tricyclic compouds as substance P antagonists
US5972930A (en) * 1996-08-14 1999-10-26 Pfizer, Inc. Pyridinylamino tricyclic compounds as substance P antagonists
US6143767A (en) * 1996-08-14 2000-11-07 Pfizer Inc Piperidinylamino tricyclic compounds as substance P antagonists
US6133264A (en) * 1997-08-19 2000-10-17 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives for inhibiting skin erythema and/or skin pigmentation
WO1999025714A1 (en) * 1997-11-19 1999-05-27 Pfizer Pharmaceuticals Inc. Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists
CZ297315B6 (en) * 1997-11-19 2006-11-15 Pfizer Inc. Piperidinylaminomethyl trifluoromethyl cyclic ether compound, its use, pharmaceutical composition in which the compound is comprised and intermediate
WO2000068224A1 (en) * 1999-05-06 2000-11-16 Pfizer Products Inc. Substituted benzolactam compounds
US6316632B1 (en) 1999-05-17 2001-11-13 Pfizer Inc Process for preparing 2-phenyl-3-aminopyridine, substituted phenyl derivatives, thereof, and salts thereof
WO2000071538A3 (en) * 1999-05-21 2001-02-22 Pfizer Prod Inc 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
US6239147B1 (en) 1999-05-21 2001-05-29 Pfizer Inc 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
AP1396A (en) * 1999-05-21 2005-04-19 Pfizer Prod Inc 1-Trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives.
CZ299029B6 (en) * 1999-10-18 2008-04-09 Pfizer Products Inc. Mixture of piperidinylaminomethyl trifluoromethyl cyclic ether compounds, and processes as well as intermediates for its preparation
EP1095655A3 (en) * 1999-10-25 2003-03-26 Pfizer Products Inc. NK-1 receptor antagonists and eletriptan for the treatment of migraine
US7612090B2 (en) 1999-11-03 2009-11-03 Albany Molecular Research, Inc. Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
US7265116B2 (en) 1999-11-03 2007-09-04 Arm Technology, Inc. Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof
WO2001077100A3 (en) * 2000-04-10 2002-03-07 Pfizer Prod Inc Benzoamide piperidine compounds as substance p antagonists
EA005409B1 (en) * 2000-04-10 2005-02-24 Пфайзер Продактс Инк. Benzoamide piperidine containing derivatives as substance p receptor antagonists
US7119207B2 (en) 2000-04-10 2006-10-10 Pfizer Inc Benzoamide piperidine containing compounds and related compounds
US7419985B2 (en) 2000-07-11 2008-09-02 Amr Technology, Inc. 4-Phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US7084152B2 (en) 2000-07-11 2006-08-01 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
US7309789B2 (en) 2000-07-11 2007-12-18 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
EP1186318A3 (en) * 2000-09-06 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6727249B2 (en) 2001-04-10 2004-04-27 Merck Sharp & Dohme Ltd. Azabicyclic ether derivatives and their use as therapeutic agents
EP2319838A1 (en) * 2002-06-07 2011-05-11 Cortical Pty Ltd Therapeutic Molecules and Methods-1
US8309594B2 (en) 2004-04-27 2012-11-13 Wyeth Llc Purification of progesterone receptor modulators
US7514466B2 (en) 2004-04-27 2009-04-07 Wyeth Purification of progesterone receptor modulators
US8609712B2 (en) 2004-04-27 2013-12-17 Wyeth Llc Purification of progesterone receptor modulators
US9499531B2 (en) 2004-07-15 2016-11-22 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US7541357B2 (en) 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9085531B2 (en) 2004-07-15 2015-07-21 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
US9403776B2 (en) 2005-07-15 2016-08-02 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007011820A2 (en) 2005-07-15 2007-01-25 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007093827A1 (en) 2006-02-15 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US11096950B2 (en) 2006-11-01 2021-08-24 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2336120A1 (en) 2007-01-10 2011-06-22 Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP2805945A1 (en) 2007-01-10 2014-11-26 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP3103791A1 (en) 2007-06-27 2016-12-14 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US9498476B2 (en) 2008-06-04 2016-11-22 Albany Molecular Research, Inc. Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US9173879B2 (en) 2009-05-12 2015-11-03 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US9604960B2 (en) 2009-05-12 2017-03-28 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
WO2010132442A1 (en) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
EP4079856A1 (en) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
EP3327125A1 (en) 2010-10-29 2018-05-30 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10624875B2 (en) 2012-11-14 2020-04-21 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014085216A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Also Published As

Publication number Publication date
DE69612003T2 (en) 2001-06-21
JP3042894B2 (en) 2000-05-22
DK0840732T3 (en) 2001-04-17
US6180647B1 (en) 2001-01-30
JPH11502861A (en) 1999-03-09
EP0840732A1 (en) 1998-05-13
CA2226292A1 (en) 1997-01-30
GR3035774T3 (en) 2001-07-31
CA2226292C (en) 2001-12-11
EP0840732B1 (en) 2001-03-07
ES2155601T3 (en) 2001-05-16
MX9800187A (en) 1998-05-31
DE69612003D1 (en) 2001-04-12
ATE199552T1 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
EP0840732B1 (en) Substituted benzolactam compounds as substance p antagonists
EP0436334B1 (en) 3-Aminopiperidine derivatives and related nitrogen containing heterocycles
EP0699199B1 (en) Heteroatom substituted alkyl benzylaminoquinuclidines as substance p antagonists
US5652246A (en) Piperidine compounds
US5346906A (en) Substituted pyridines, their preparation, formulations and use in dementia
CA2109415C (en) Substituted 3-aminoquinuclidines
AU598149B2 (en) 2-((4-piperidyl)methyl)-1,2,3,4-tetrahydroisoquinoline derivatives, their preparation and their application in therapy
US20030105124A1 (en) Substituted benzolactam compounds
RU2090565C1 (en) Racemic or optically active perhydro-1h-pyrido-[1,2-a]-pyrazines or their pharmaceutically acceptable salts and method of their synthesis
US6288225B1 (en) Substituted benzolactam compounds as substance P antagonists
EP1175417B1 (en) Substituted benzolactam compounds
US5789423A (en) 3- 5-substituted benzyl)amino!-2-phenylpiperidines as substance P antagonists
AU628735B2 (en) Cerebral function enhancing pyrimidinyl derivatives
CA2215020C (en) Tetrazolyl-substituted quinuclidines as substance p antagonists
IE67871B1 (en) Novel benzothiopyranylamines
US20020052503A1 (en) Substituted benzolactam compounds as substance p antagonists
US6143767A (en) Piperidinylamino tricyclic compounds as substance P antagonists
PT840732E (en) SUBSTITUTED BENZOLACTAN COMPOUNDS AS ANTAGONISTS OF THE SUBSTANCE P
MXPA01011367A (en) Substituted benzolactam compounds
JPH1081684A (en) Substituted 3-aminoquinuclidine drug compositions
HK1068136A1 (en) Muscarinic antagonists
HK1068136B (en) Muscarinic antagonists
JPH1072464A (en) Piperidinylamino tricyclic compounds as substance P antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1997 505628

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996911079

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2226292

Country of ref document: CA

Ref document number: 2226292

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/A/1998/000187

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 08983004

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1996911079

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1996911079

Country of ref document: EP